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Yellow Fingers 
 
Another wheeze, breathlessness, 
Rousing sighs move the stethoscope’s air. 
Curious eyes fill with hesitating hope. 
But yellow fingers cry out beware. 
 
Disease was always imminent, 
Indeed, the nicotine-scent could tell. 
One more victim, one more defeat, 
One more who wishes to get well. 
 
An instant of weightlessness, 
Like a car breaking through the fence. 
Time dangled frozen, for a moment, 
Until the news broke the suspense. 
 
What treatment to begin with, 
While coping with denial and despair? 
Could recovery still be a possibility, 
Or need we shift from cure to care? 
 
Medical visits more regularly, 
To monitor deterioration every other day, 
Soothe grief and discomfort carefully, 
Discuss acceptance, if that is okay. 
 
Craving for relief of pain and misery, 
And delayed what alas cannot be escaped. 
When comfortably numb on medication, 
A final decision is now to be made: 
 
Should life be lived, 
In this heartless 
Shape 
? 
 
 
Wouter van Dijk 
Journal of Palliative Medicine. 2013;16(2):211 
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General Introduction and Outline 
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hronic obstructive pulmonary disease (COPD) is a common progressive disease 
characterized by not-fully reversible airflow obstruction, increasing mortality and 
morbidity worldwide.
1
 With a prevalence of 10 to 20% among adults older than 40 
years, the life-time incidence of COPD is estimated up to 25% of the general population.
2-4
 
Cigarette smoking is the cause of developing COPD in approximately 80% of patients, 
whereas smoking is one of the main causes of cardiovascular disease.
1,5
 Although cessation of 
cigarette smoking is the best intervention to prevent disease development and/or 
progression,
6-10
 on average 20 to 30% of the worldwide population are current smokers.
11,12
 
Within the group of COPD patients, cessation efforts are only modest: 50% of patients 
continue smoking.
13,14
 
 
Bronchodilators are the cornerstone of symptomatic treatment in COPD patients. These 
agents reverse pulmonary obstruction, reduce sputum production, and decrease coughing.
1
 
The pulmonary function tends to improve through acting on the bronchiolar smooth muscles, 
which may result in lesser hyperinflation – reduced pulmonary dead space – and a correlated 
relief of symptoms like dyspnoea and constrained exercise tolerance.
15-18
 Since usually 
administered by inhalers, the pharmacologic action of bronchodilators is facilitated locally at 
the pulmonary tissue with consequently little systemic (side-)effects. There is a tendency 
towards the use of long-acting bronchodilators, as they improve symptoms more effectively; 
over 50% of patients across different COPD severity stages use one or more long-acting 
bronchodilators.
13,19
 
 
Furthermore, COPD is associated with several comorbidities, including cardiovascular 
disease. In addition to sharing the same major risk factor, i.e. cigarette smoking, these two 
diseases are independently related. Prevalence of cardiovascular disease varies across 
different COPD populations, but mainly consists of ischemic heart disease and heart failure 
(table 1). Likewise, COPD patients are at increased risk to develop cardiovascular disease 
compared to controls without COPD, younger patients in particular.
20-22
 
 
Although both the main prognostic factor and the main pharmacologic treatment in COPD, 
i.e. smoking and bronchodilation, respectively, have been studied extensively, their 
interaction and its effect on (cardiovascular) mortality have not. COPD is a highly prevalent 
disease, associated with cardiovascular disease, and while half of the diagnosed COPD 
population persists in their smoking habit, most patients use some sort of bronchodilator.
4,13,23
 
Hence, study of their interaction would be relevant for the decision on pharmacologic 
treatment of many patients. In this thesis, we present our studies that concerned the 
characterization of cigarette smoke followed by our studies that explored the interaction 
between smoking and bronchodilators in COPD patients. In particular, we discuss the safety 
of bronchodilators in COPD patients who concurrently smoke cigarettes. 
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Table 1. Prevalence of co-morbidities in diagnosed COPD patients and matched controls, adapted 
from: clinics from general population, California, USA,
1
 first-time diagnosis of COPD from primary 
care, UK,
2
 and from general population, Saskatchewan, Canada.
3
 
 California
$
 UK^ Saskatchewan
$
 
 
COPD 
N=45,966 
Control * 
N=45,966 
COPD 
N=35,772 
Control * 
N=35,772 
COPD 
N=11,493 
Control * 
N=22,986 
COPD prevalence >40 years 3%
$
 5%^ 2.6%
$
 
Sex (male) 55.4% 55.4% 51.3% 51.3% 54% 54% 
Age mean (years) 64.4 64.4 65-69 65-69 n/a n/a 
Smokers 
Current 
Former 
Unknown 
 
n/a 
n/a 
n/a 
 
n/a 
n/a 
n/a 
 
43.3% 
25.3% 
9.8% 
 
18.0% 
18.0% 
13.7% 
 
13% 
64% 
2.4% 
 
6% 
44% 
1.3% 
Diabetes 1.6% 1.1% n/a n/a 14.5% 12.4% 
Ischemic heart disease 2.8% 0.6% 18.3% 15.6% 8.9% 4.3% 
Stroke 1.2% 0.5% 6.9% 5.9% 4.8% 3.3% 
Heart failure 7.2% 0.9% 8.4% 3.5% 19.0% 3.7% 
Arrhythmia
#
 8.2% 1.9% 7.2% 6.4% 11.3% 5.2% 
n/a: not available; * Matched for gender and age; 
#
 Ventricular tachycardia and/or fibrillation, cardiac arrest, 
atrial fibrillation, other. 
$
 Only patients with at least 2 COPD drug prescriptions. ^ Based on previous 
prevalence study.
4 
1. Sidney S, Sorel M, Quesenberry CP, Jr., et al. COPD and incident cardiovascular disease hospitalizations 
and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128:2068-2075 
2. Schneider C, Bothner U, Jick SS, et al. Chronic obstructive pulmonary disease and the risk of 
cardiovascular diseases. Eur J Epidemiol 2010; 25:253-260 
3. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive 
pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 
16:63-70 
4. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in 
the UK. Thorax 2000; 55:789-794 
 
Cigarette smoke and cardiovascular disease 
Apart from causing other diseases, cigarette smoking increases the risk to develop both COPD 
and cardiovascular disease.
1,5
 Made primarily from dried tobacco leaves, over 1,000 additives, 
ranging from citric acid to oak moss, are available to create cigarettes with a distinctive 
flavour, to moisturise, to preserve and to ease manufacturing processes.
24
 All ingredients 
finally contribute to the complex mixture of cigarette smoke constituents. Over 4,800 
constituents have been identified yet, of which many can be hazardous.
25
 These constituents 
occur in cigarette smoke as particulate matter, volatile substances or as gasses.
26,27
 Absolute 
smoke yields are difficult to study, since smoke characteristics are highly dynamic over time 
and vary across different smokers, cigarette properties and smoking conditions.
28,29
 Fractional 
risk attributions of specific substances to develop disease are indefinite and pathogenic 
mechanisms of action vary across the smoke substances.
29,30
 Altogether, these include local 
and systemic carcinogenic effects, local inflammation, and finally systemic inflammation and 
systemic toxic effects, which are both important factors in causing atherosclerosis and 
cardiovascular disease.
27,31-35
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Bronchodilators and cardiovascular disease 
The effect of bronchodilators on disease progression and (cardiovascular) mortality in COPD 
patients has been studied considerably. The first concern on bronchodilator safety in COPD 
patients was raised in 2002 by the Lung Health Study, a randomized trial including 5,887 
patients with five year follow-up, performed during the early 1990’s. Short-acting muscarinic 
antagonists appeared to increase fatal and/or nonfatal cardiovascular events from 5.50% in the 
placebo group to 6.94% in the bronchodilator group.
36
 
 
Currently, general conclusions on the (adverse) effects of bronchodilators are mainly based on 
the results of the two largest trials: TORCH and UPLIFT.
18,37,38
 Both studies on COPD 
patients were rather powerful as they involved large multicenter trials on long-acting 
bronchodilator efficacy and safety, compromised around 6,000 patients and had a follow-up 
of 3 to 4 years, respectively. TORCH studied long-acting beta-agonists (LABA), and did not 
reveal a significant difference between treatment and placebo groups: an all-cause mortality 
of 13.5% versus 15.2% was observed, and cardiovascular major adverse events occurred in 
22.7% versus 24.2%, respectively.
18,37
 UPLIFT studied long-acting muscarinic antagonists 
(LAMA), and revealed a decrease in mortality from 16.3% to 14.4% favoring the 
bronchodilator group over the placebo group. There was no significant difference for 
cardiovascular mortality, although cardiovascular causes were only <10% of all-cause 
mortality.
38
 However, both study methods enclosed some restrictions due to tolerant selection 
criteria to increase participation numbers, that resulted in a mixture of different participant 
characteristics that unfortunately were not entirely representative for the whole COPD 
population. In addition, their protocols allowed the utilization of possible confounding 
comedication.
39
 
 
An early meta-analysis of LABA (without TORCH) in patients with asthma or COPD did not 
reveal an increased risk of bronchodilators for cardiovascular major adverse events: risk ratio 
(RR) 1.61 (95% CI 0.76 to 3.42).
40
 Meta-analyses that explored the effect of LAMA 
(including UPLIFT) on cardiovascular mortality in near 20,000 patients revealed rather 
different RR in favor of the bronchodilator, although their methods were rather similar: RR 
0.93 (95% CI 0.73-1.20), and RR 0.77 (95% CI 0.60-0.98).
41,42
 Finally, a meta-analysis of 
6,522 patients that concerned the same drug administered by mist inhalers, revealed an 
increased risk for all-cause mortality and cardiovascular mortality: RR 1.52 (95% CI 1.06 to 
2.16), and RR 2.05 (95% CI 1.06 to 3.99), respectively.
43
  
 
Altogether, the effect of bronchodilators on (cardiovascular) mortality and morbidity remains 
questionable, as study results are contradicting.
18,38,40,41,43
 Moreover, an interaction between 
bronchodilators and smoking might explain part of the reported discrepancies, but so far only 
little effort was spent on exploring this interaction. 
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Interaction between smoking and bronchodilators 
In order to clarify the deadlock on the bronchodilator safety profiles, we hypothesized an 
interaction between the primary pharmacologic treatment and the main prognostic factor, i.e. 
bronchodilation and smoking.
44
 Apart from a competitive mechanism of action on 
(cardiovascular) mortality and hence the protective effect of bronchodilators being overruled 
by the toxic effect of smoking, bronchodilators might change the smoking toxicity itself. By 
modifying coughing and pulmonary function – including less hyperinflation – bronchodilators 
may change the depth, volume and time of smoke inhalation patterns along with a change of 
other smoking habits. Smoke penetration and retention depends on this smoke inhalation 
depth, volume and time, through particle size-dependent mechanisms of diffusion and 
deposition.
45,46
 As the amount of cigarette exposure is positively correlated with the risk to 
develop cardiovascular disease,
5,47
 an altered pulmonary retention and penetration of smoke 
substances due to changed smoking (inhalation) patterns may consequently result in a 
different (cardiovascular) disease risk profile. In addition, muscarinic antagonists decrease 
sputum production after a few days. Sputum may act as a natural barrier that traps smoke 
particles and prevents these to penetrate the pulmonary tissue. A change of this natural barrier 
may hence affect overall smoke toxicity as well. 
 
As mentioned previously, so far little effort has been involved to study the interaction; only 
post-hoc analyses of the two large bronchodilator trials are available. TORCH did not reveal 
an interaction between treatment and smoking, although details were not reported.
18
 UPLIFT 
revealed a different effect of tiotropium on all-cause mortality for participants that continued 
smoking and those that had quit smoking: the hazard ratio in continuing smokers was 1.24 
(95% CI 0.90 to 1.70) versus 0.81 (95% CI 0.69 to 0.96) in continuing ex-smokers, never-
smokers were not included.
38,48
 In addition, one meta-analysis reported a trend that substantial 
smoking (>55 pack years) may have a modifying effect on cardiovascular major adverse 
events due to tiotropium: tiotropium risk ratio was 0.87 (95% CI 0.74 to 1.03) in patients <55 
pack years, compared to 1.51 (95% CI 0.79 to 2.81) in patients >55 pack years (p = 0.09).
41
 
However, these trials allowed patients in the placebo groups to use several other 
bronchodilators other than the study drugs, and none of the papers reported sufficient 
statistical details on the interaction itself. 
 
Following the hypothesis of interaction between bronchodilation and smoking, and as a 
possible missing link in the discussion on bronchodilator safety profiles, we further explored 
this interaction in more detail. This thesis reports on the findings of a trial that explored the 
effect of interaction on smoke retention as well as additional studies that explored the effect of 
interaction on subsequently developing cardiovascular disease. 
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OUTLINE OF THE DISSERTATION 
 
To facilitate the study of interaction, the (dynamic) properties of cigarette smoke as measured 
by size-resolved particle distributions are first presented in this thesis. In addition to the 
exploration of nanoparticles in fresh and undiluted cigarette smoke (particle diameter <100 
nm, chapter 2.1), a study is described that concerns submicron particles (particle diameter 
100 – 1000 nm, chapter 2.2). Both studies show the comparison of the size distributions with 
tar values as claimed on cigarette packs. These studies show that in terms of size units most 
particles are larger than 100 nm, and confirm that their measurement is highly dependent on 
cigarette conditions (e.g. filter ventilation, tar values, humidity), smoking behavior, dilution, 
and ageing. These findings are important for our method to measure smoke retention in the 
interaction in COPD experiment (ICE) as reported in the succeeding chapters. 
 
The report of interaction between smoking and bronchodilators in COPD patients is initiated 
with a detailed description of its hypothesis in chapter 3.1. This chapter also explains its 
relevance, as it would affect a large population of COPD patients who have bronchodilators 
prescribed whilst they persist in their smoking habit. Next, the exploration of the 
aforementioned hypothesis begins with a pilot study by a secondary analysis of a cohort of 
COPD patients from a Dutch primary care laboratory centre (chapter 3.2). The data from this 
population offered the possibility to study the effect of the interaction on cardiovascular non-
fatal events as measured by the new prescription of specific medication, used for the 
secondary prevention of cardiovascular disease. 
  
Chapter 3.3 follows with a detailed method description of a randomized controlled crossover 
trial for investigating the effect of bronchodilation on pulmonary smoke retention, which 
results are presented in chapter 3.4. The study included 39 COPD patients who smoked 
cigarettes under standardized conditions, both during maximal bronchodilated and during 
undilated conditions. Following the study of the basic mechanisms of smoke retention in 
COPD patients, chapter 3.5 continues with the exploration of the long-term effect of the 
interaction on the risk to develop cardiovascular disease. This quest is studied by a secondary 
analysis of a large cohort of COPD patients, which were followed for five years during the 
1980’s and 1990’s. Their data included smoking status, use of bronchodilators and 
cardiovascular outcome, and hence facilitated to study the final effect of interaction on the 
risk to develop cardiovascular disease. In chapter 4, a general discussion is presented to 
outline the most striking findings of these studies on interaction, including their interpretation 
and their relevance for future pharmacologic treatment in COPD patients who persist in their 
smoking habit. A summary of the thesis is presented in chapter 3.5. 
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ABSTRACT 
 
Background. Cigarette smoke is a complex mixture of smoke constituents, often 
characterised by size-resolved particle distributions. Since descriptions of ultrafine particles 
<50 nm are absent, our aim was to explore the existence of these nanoparticles in fresh and 
undiluted cigarette smoke. 
 
Methods. We measured undiluted smoke particles real-time by a scanning mobility particle 
sizer with Faraday cup electrometer, integrated in our custom-made smoking machine. 
Cigarettes were smoked by 2 second puffs, 30 second puff intervals, and 50 ml puff volume. 
We tested 6 different cigarettes  (1 - 10 mg tar per cigarette) at 10 particle size-ranges 
between 6 and 50 nm, and repeated measurements 5 times. 
 
Results. The formation of nanoparticles in fresh cigarette smoke was observed over the entire 
range between 6 and 50 nm, and reproduced in all cigarettes. The highest mean yield was 8.8 
x 10
9
 (SD = 1.1 x 10
9
) particles per cigarette at the largest particle size range by high-tar 
cigarettes. Nanoparticle counts appear to increase with particle size, claimed tar values and 
blocking of filter ventilation holes, and inversely with butt length. 
 
Conclusion. Fresh undiluted cigarette smoke contains large amounts of potentially toxic 
nanoparticles <50 nm. We recommend to further study nanoparticles in the characterisation of 
cigarette smoke. 
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igarette smoke is a complex mixture of potentially pathogenic smoke constituents, 
including particulate matter, volatile substances and gasses. Several techniques that 
characterize cigarette smoke have been reviewed during the last century, including 
the current method to categorise cigarettes by tar, nicotine and carbon monoxide content.
1-3
 
Techniques that analyse smoke constituents more specifically and usually in relation to tar 
yields include single constituent analyses,
1;4-7
 and size-resolved particle distributions by 
different spectrometry methods.
8-12
 
 
Limitations of measurement techniques include low time resolution, aerosol (ageing) 
dynamics and high particle concentrations, which causes the need for (possibly time-delaying) 
dilution.
1;8
 Particles consequently agglomerate substantially before measurement, apart from 
evaporation, condensation, diffusion and (gravitational) sedimentation.
1
 Mainly due to these 
limiting measurement factors, until recently, only two reports have been published of smoke 
particles below 100 nm in diameter.
9;10
 The first used orifices of 0.5 mm whereas the other 
needed a dilution of 80,000:1, which are both important limitations. Recently, nanoparticles 
have been studied more extensively by real-time size-resolved particle distributions for 
instance by electrical low-pressure impactor and differential electrical mobility particle 
spectrometry.
8;12-14
 These techniques are able to measure particles down to 5 nm. Both 
techniques however implicated dilutions of 50:1 and 750:1 and time delays range from 0.2 
seconds to 1.5 seconds. Furthermore, the related studies only report the count median 
diameter and do not explicitly study nanoparticles. Some figures however do reveal the 
existence of nanoparticles upward of 70 nm.
8;12
 Still, little is known about particles smaller 
than 70 nm. Nanoparticles either are very difficult to measure with the available techniques or 
are only scarce. As particles are abundant above 100 nm and as the largest amount of cigarette 
smoke has been reported to result from gasses with diameters of around 0.5 nm,
1
 one might 
consequently expect large quantities of particles within the size-range between 1 and 100 nm. 
The existence of nanoparticles in cigarette smoke would be quite relevant as they likely have 
a higher deposition and transposition and thus a higher toxic potency.
15;16
  
 
We hypothesise the existence of large quantities of nanoparticles above 5 nm. The Scanning 
Mobility Particle Sizer with Faraday Cup Electrometer (SMPS+E), by Grimm Aerosol 
Technik, measures concentrations up to 10
8
 particles per cm
3 
and is able to detect 
nanoparticles from 6 to 1100 nm real-time. SMPS+E measurements are based on size-specific 
electrical loading of particles and subsequently size-specific electrical and mechanical 
mobility of particles. The SMPS+E appears to have promising qualities in this, so far, poorly 
explored particle size range within cigarette smoke.  
 
Our aim in this study is to explore this existence of nanoparticles in fresh unaged and 
undiluted cigarette smoke, and to determine their contribution to human cigarette smoke 
exposure, i.e., their contribution to human health-hazard. Since filter ventilation is a very 
important factor in altering (particle size-resolved) smoke yields,
8;12;17
 by dilution and by 
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altering combustion, we also explored the influence of filter ventilation on the appearance of 
nanoparticles. 
 
 
METHODS 
Study design 
The main levels that influence smoke measurements include production, collection and 
measurement itself. We standardised smoke production by a custom-made smoking machine, 
integrated in our SMPS+E (figure 1), which consequently standardised the smoke collection 
and allowed standardisation of the measurements. By a pilot study (not reported), we adjusted 
the smoking regime and measurement settings so we ended up with a standardised method 
that produced typical and valid smoking interval-dependent particle counts.
12
 We selected a 2 
second puff, 30 second interval, 50 ml puff volume, and 10 continuous 8 Hz single channel 
measurements, with geometric mean particle diameters between 5.65, and 50.38 nm at 5 nm 
intervals. Each channel covers a size range of approximately 1 nm. We measured 6 cigarettes 
with different filter ventilation capacities and different determined tar mass yields, and each 
cigarette measurement was repeated 5 times: 3 cigarettes manufactured by Phillip Morris and 
3 by British American Tobacco as displayed in table 1. 
 
 
Figure 1. Schematic test formation. The valve inlets are connected to a cigarette and to clean room air. 
A timer controls the valve inlets. The DMA controller ensures a continuous flow of 1.5 l/min. DMA: 
differential mobility analyzer. Connections are by carbosilicon tubing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMA controller 
SMPS long-DMA 
Faraday Cup 
Electrometer 
SMPS inlet  
and impactor  
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Table 1. Cigarette brands, from Dutch markets, used for smoke measurements, categorised by their 
tar, nicotine and CO amount. Lower tar amount resembles higher filter ventilation. 
Cigarette Brand Tar (mg) Nicotine (mg)  CO (mg) 
Phillip Morris    
Marlboro Red 10 0.8 10 
Marlboro Flavour plus 6 0.4 8 
Philip Morris One 1 0.1 2 
British American Tobacco    
Kent Futura 8 0.7 10 
Kent original taste 4 0.4 5 
Kent Infina 1 0.1 2 
 
 
Smoke production 
Smoking was based on the constant air-flow of the spectrometer, which was connected to the 
4 mm valve outlet by inert carbosilicon tubing. The setting included a 2-way valve with two 4 
mm inlet orifices that allowed smoking through the orifice with the cigarette attached and 
allowed a smoking interval through the other orifice with clean room air attached. A timer 
that managed the valve direction could subsequently adjust puff duration and frequency. We 
ignited cigarettes electrically and smoked cigarettes up to 32 mm from the filter end. All 
cigarettes were smoked with their filters inserted 2 cm in the filter holder. The 3 cigarettes 
manufactured by Phillip Morris were also smoked with their filters inserted 1 cm, and their 
main filter ventilation holes uncovered. Cigarettes were stored beforehand at 22 °C and at 
60% relative humidity for at least 2 days. 
 
Study outcome 
We defined the size-resolved particle distribution per smoked cigarette as our outcome. 
Particle distributions are presented as lognormal size distributions: dN/dln(D) per ml 
produced smoke – dN equals particle count, dln(D) equals lognormal channel size range.18 
For each channel, the total particle count of one cigarette measurement was derived from area 
under the curve calculations from all successive 2 second puff periods. We multiplied the 
mean particle concentration per puff by 50, to attain the particle number per 50 ml puff 
volume. We calculated the mean total particle count of 5 different measurements. 
 
Analysis 
We analysed mean channel particle counts, including standard deviation (SD) and coefficients 
of variation. Test of normality for distributions was performed by Shapiro-Wilk (p< 0.05).
19
 
We compared particle counts of different cigarette types and filter ventilation blocking 
conditions, and performed analysis of variance (ANOVA) for each separate channel. We used 
SPSS 16.0 for all analyses. 
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RESULTS 
Filters inserted 2 cm 
By evaluating the interval-dependent particle counts, we observed valid smoke peaks lasting 
1/8 to 2 seconds at all channels for all 6 cigarettes. However, at 46 nm and 50 nm, some puffs 
attained the maximum concentration measurable, particularly in high-tar cigarettes. Particle 
counts per puff were higher at smaller butt lengths, due to an increase of both the peak height 
and duration (figure 2). Coefficients of variation of total particle counts per cigarette ranged 
from 5% to 92% (mean 22%) for different channels. Tests of normality revealed 4 non-
parametric distributions out of 60 tests.  
 
Figure 2. An example of time-dependent particle numbers within a puff, measured 
for Marlboro Red, at 41 nm by 2 different puffs. 
 
 
For cigarettes manufactured by Phillip Morris, the lowest particle yield was at 6 nm by Philip 
Morris One, 2.6 x 10
6
 (SD 1.2 x 10
6
) particles per cigarette, whereas the highest yield was at 
50 nm by Marlboro Red, 8.8 x 10
9
 (SD = 1.1 x 10
9
) particles per cigarette. We observed that 
particle counts increased parallel to particle diameter size similarly across different cigarette 
types (figure 3). Although particle counts differed significantly between different cigarette 
types (table 2), they did not differ much below 40 nm, whereas above 40 nm the highest tar 
cigarette revealed excessive particle yields due to a very rapid increase. 
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Table 2. Analysis of variance (multiple comparisons by Least Significant Difference test, homogeneity 
of variance assumed) between different cigarette types for ten different channels ranging between 6 and 
50 nm, based on 5 different measurements. 
 
6nm 10nm 15nm 20nm 25nm 30nm 36nm 41nm 46nm 50nm 
Filter inserted 2 cm 
          
Marlboro 0.00 0.00 0.00 0.01 0.00 0.00 0.28 0.09 0.01 0.00 
Marlboro Flavour Plus 
A
 
A
 
A
 
A,B
 
A
 
A
 
A
 
A,B
 
A,B
 
A
 
Philip Morris One 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.32 0.13 
Kent futura 0.00 0.01 0.03 0.20 0.00 0.00 0.01 0.17 0.00 0.00 
Kent original taste 
A
 
A
 
A
 
A
 
A
 
A
 
A
 
A
 
A
 
A
 
Kent infina 0.00 0.03 0.78 0.01 0.27 0.08 0.11 0.85 0.79 1.00 
Filter inserted 1 cm 
          
Marlboro 0.05 0.46 0.54 0.79 0.22 0.00 0.03 0.04 0.42 0.11 
Marlboro Flavour Plus 
A,B
 
A,B
 
A,B
 
A,B
 
A,B
 
A
 
A,B
 
A
 
A,B
 
A,B
 
Philip Morris One 0.76 0.36 0.46 0.53 0.58 0.52 0.12 0.04 0.08 0.00 
A
 p values for difference with redundant variable 
B
 Homogeneity of variance not assumed (multiple comparisons by Games–Howell) 
 
 
Figure 3. Size-resolved particle distribution of cigarettes manufactured by Philip 
Morris, smoked with 2 cm filter insertion at 2 second puffs, 30 second intervals and 
50 ml puff volume. 
 
 
We observed the lowest particle yield in Kent cigarettes at 6 nm by Kent Infina, 3.0 x 10
6
 (SD 
9.4 x 10
5
) particles per cigarette, and the highest yield at 50 nm by Kent Futura, 5.8 x 10
9
 (SD 
1.3 x 10
9
) particles per cigarette (figure 4). Again, particle yields increased similarly along 
with particle diameter size across the different cigarettes, with highest yields for the highest 
tar cigarette (Kent Futura), significant at most channels. However, differences were relatively 
small compared to claimed tar mass yields. 
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Figure 4. Size-resolved particle distribution of cigarettes manufactured by British 
American Tobacco, inserted 2 cm and smoked at 2 second puffs, 30 second 
intervals and 50 ml puff volume. 
 
 
Filters inserted 1 cm 
3 cigarettes were also tested with unblocked filter ventilation holes as well. For these 
cigarettes, we observed valid smoke peaks only  at particle sizes upward of 30 nm, based on 
the shapes and height of the smoke peaks, peak intervals, and the standard deviations of the 
particle counts per cigarette. Figure 5 shows an example of particle numbers measured at 41 
nm. Below 30 nm, these peaks appeared scarce and with random intervals, and relatively large 
standard deviations. Between 30 nm and 50 nm coefficients of variation ranged from 9% to 
101% (mean 49%). Tests of normality revealed 2 non-parametric distributions out of 15 tests. 
Particle counts per puff again were higher at smaller butt lengths, increased along with 
particle diameter size, and appeared to be reflected by claimed tar mass yields (figure 6). 
Compared to smoking with blocked filter ventilation holes, the yields of all cigarettes tended 
to decrease about 10-fold at each channel, but mainly affected Philip Morris One cigarettes 
with high filer ventilation capacity.  
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Figure 5. Example of smoking interval-dependent particle numbers for Marlboro 
Flavour plus, measured at 41 nm, for 13 successive puffs. Smoke was produced by 
2 second puffs, 30 second intervals, 50 ml puff volume, and filter insertion of 1 cm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Size-resolved particle distribution of cigarettes manufactured by Philip 
Morris, smoked with 1 cm filter insertion at 2 second puffs, 30 second intervals and 
50 ml puff volume. 
 
 
 
 
 
 
2.1 
26 
 
DISCUSSION 
Although previous studies on cigarette smoke did not explicitly report on nanoparticles 
between 6 and 50 nm, our study reveals their existence in fresh and undiluted smoke, from 
cigarettes smoked by 2 second puffs, 30 second intervals, and 50 ml puff volumes. We 
managed to reproduce the results in different cigarette types and by different filter ventilation 
blocking. For a single channel measurement, the highest mean yield was 8.8 x 10
9
 (SD = 1.1 x 
10
9
) particles per cigarette. 
 
Nanoparticle counts appear to increase with particle size, claimed tar values and blocking of 
filter ventilation holes, and inversely with butt length. Although high-tar cigarettes seem to 
have an overall excess of particles compared to lower tar cigarettes, the channel-based ratios 
between the particle yields vary. 
 
Validation 
Variation of size-dependent particle counts within a certain cigarette appear comparable to the 
variations of tar measurements within a certain cigarette. Apparently, most of our observed 
variation is due to natural variations within the cigarettes themselves. In addition, our results 
revealed smoking interval-dependent particle counts, and the increase of particle counts for 
successive puffs corresponds to the results of prior studies.
8;11
 Alas, at two channels – 46 and 
50 nm – we sometimes attained the concentration threshold, particularly in high-tar cigarettes. 
Furthermore, in our pilot study, we observed a lower limit of necessary smoking intensity, 
that suggests nanoparticles require combustion circumstances that not necessarily always 
occur during real-life smoking. Altogether, we believe our method is valid in measuring fresh 
and undiluted cigarette smoke, though the two largest channels might underestimate the 
particle counts in high-tar cigarettes.  
 
Interpretation 
Although the interpretation of our results appears confined to our smoking regime and 
selection of cigarettes, the possibility to generalise our results is tempting. Since our smoking 
regime is moderate compared to other common used regimes and our selection of cigarettes 
cover a wide range of cigarette types, we assume some general remarks on our results may be 
allowed.
1
 
 
Although we hypothesized high particle counts, compared to previous studies that report size-
resolved particle distributions in fresh cigarette smoke, the contribution of our encountered 
nanoparticles would be only a few percents.
8
 Even more, the particle counts decreased for 
smaller particles. Possibly, the small nanoparticles have a high potency to quickly 
agglomerate into larger smoke constituents or to disperse into smaller molecules due to their 
volatile properties. In addition, the increase of nanoparticle counts due to smaller butt lengths, 
also suggests crucial time-dependent agglomeration and evaporation in successive puffs, apart 
from improved combustions and decreased tobacco-dependent filter potency, which has 
27 
 
already been observed for larger particles.
8;12
 However, by a possibly increased deposition in 
and transposition through the pulmonary tissue, the probably excessive toxic properties of 
these nanoparticles would still indicate a substantial contribution in health-hazard.
15;16
 
 
Overall, the particle yields seem to depend on claimed tar values, with higher yields for 
higher-tar cigarettes.Although the particle counts only roughly reflect the size resolved 
particle distributions, it suggests an overall enhanced combustion and increased production of 
all particles for higher-tar cigarettes but maybe also a different combustion with different size-
resolved particle distributions.  
 
Interpretation of (blocking of) filter ventilation holes was only possible for channels ≥ 30 nm. 
However, a more intense regime by ventilation blocking seems to excessively increase 
nanoparticle counts in both high-ventilated and low-ventilated filters. Although an excess of 
particles by vent-blocking – as measured by tar yields and carbon monoxide – has already 
been observed particularly in high-ventilation cigarettes,
20
 the production of nanoparticles is 
influenced substantially by low-ventilation as well. Otherwise, we might have encountered a 
tipping point for combustion requirements. In addition, the differences between Philip Morris 
One and Marlboro Red cigarettes were smaller when ventilation holes were blocked, which 
equalises dilution and combustion circumstances across different cigarette types. The 
remaining differences in particle yield however, indicate that other factors like porous 
cigarette papers, expanded tobacco and reconstituted tobacco sheet, have a substantial 
influence on nanoparticles as well. These effects seem to be more pronounced on the 
formation of nanoparticles than expected from their effects on tar yields.
21
 
 
In conclusion, when cigarettes are smoked by moderate smoking regimes, fresh and undiluted 
cigarette smoke contains an abundance of nanoparticles, which has not been described 
previously. These particles are present in such amounts and likely have relatively high toxic 
properties. Therefore, a substantial toxic effect on human health can be expected. The 
production of nanoparticles requires a minimum smoking intensity, and is related to particle 
size, filter ventilation holes, butt length, and claimed tar values. We suggest to further study 
the necessity of measuring these particles in the smoke characterisation of different cigarettes. 
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ABSTRACT 
 
Background. Cigarette smoking causes devastating disease worldwide. Current cigarette 
classification is based on standardised tar mass values obtained from smoking-machines. 
However, their ability to predict disease is poor, and these mass values are primarily 
determined by larger particles. The aim of our study is to investigate in how far claimed tar 
values also reflect smaller tar particles in cigarette smoke. 
 
Methods. We developed a method to measure size-resolved particle distributions based on 
experimentally selecting conditions that revealed the least variety within different smoking 
regimes, puff numbers, diluted and undiluted ageing times, and filter taping. Next, we 
analysed three cigarettes types with different tar values. Cigarettes were smoked by a 
Cerulean SM-450 smoking machine, and subsequently smoke samples were diluted and 
collected in Tedlar® bags and measured for size-resolved particle distributions by a universal 
optical aerosol spectrometer. 
 
Results. Our method involved a smoking regime according to ISO 3308, the sixth puff, and 
no delayed ageing. We attained valid size-resolved particle distributions between 250 and 
1,000 nm. The results revealed similar total particle counts across different cigarette types, 
though with different size-resolved particle distributions. In particular, smaller particles in 
lower tar cigarettes were underestimated.  
 
Conclusion. We developed a method to investigate submicron size-resolved particle 
distributions in cigarette smoke in order to compare cigarettes with different tar values. Our 
study suggests that mass-based tar values are a poor reflection of smaller particles in 
mainstream cigarette smoke, and hence supports the opinion that current tar values are a poor 
predictor of disease-risk and therefore that they are deceptive to smokers. 
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igarette smoking, including passive smoking, is a vital health hazard worldwide, 
mainly related to devastating diseases such as lung cancer, cardiovascular disease and 
chronic obstructive pulmonary disease (COPD).
1;2
 Worldwide, the percentage of 
smokers seems to have stabilised at 20-30%.
1;3
 All cigarette ingredients – mainly dried 
tobacco leaves combined with a selection of over 1,000 additives – contribute to the complex 
mixture of smoke constituents. Approximately 4,800 potentially hazardous constituents have 
been identified to date.
4
 ‘Tar’ refers to the particulate matter which is trapped using 
Cambridge filters that collect 99.9% of particles >100 nm.
5
 
 
Tar values have been used to predict smoke exposure and subsequent disease risk, as these are 
assumed to be associated with all hazardous constituents and therefore, proportionately, to 
disease.
6;7
  This mass-based value is determined using smoking machines in standardised 
testing methods that have not been developed to predict individual exposure to cigarette 
smoke and subsequent disease.
8-10
 Indeed, individual exposure can be substantially modified, 
resulting in a final smoke exposure from low-tar cigarettes that is almost equivalent to full 
blend cigarettes.
11-14
 Furthermore, while some hazardous constituents have been reported to 
be disproportionately high in (ultra)low-tar cigarettes,
15
 no fractional risk attributions have 
been defined that link specific constituents to the development of disease.
16;17
 The relation 
between tar values and disease is far from absolute. Low-tar and low-nicotine cigarettes 
appeared to worsen outcomes in embryogenesis compared to regular-tar cigarettes,
18
 and a 
relation between tar values and disease was lacking or even inversed for tar values <21 mg 
per cigarette.
19;20
 Unfortunately, the ability of tar to predict disease clearly remains poor. 
Though there have been calls to change smoking standardisation, many countries still oblige 
manufacturers to inform consumers by displaying these claimed values on cigarette packs.
10
  
 
Tar values are based on particle mass, even though mass is considered to be an inferior 
measure of toxicity compared to particle count and surface area.
21;22
 Total particle mass is 
dominated by larger particles, while actual particle sizes range from 200 to 600 nm, with 
some additional particles between 100 and 1,000 nm.
23-25
 In investigating the deceptive 
implications of claimed tar values, we hypothesised that mass-based tar values only fairly 
reflect the relatively small quantity of larger tar particles, thus providing another reason to 
question the reliability of cigarette standardisation based on tar values as displayed on 
cigarette packs. The aim of our study is to develop a valid measurement method that can be 
used to investigate the ability of tar yields displayed on cigarette boxes to reflect submicron 
tar particles in mainstream cigarette smoke. 
 
 
METHODS 
Study design 
Since smoke yields depend on cigarette design and standardised parameters including 
humidity, smoke generation (puffing), collection and measurement,
16
 we developed a valid 
C 
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method that measures size-resolved particle distributions based on experimentally selected 
conditions (Table 1) that show the least variety among ten different smoke samples: puff 
sequential number (2, 4, 6, 8, 10), smoking regime (Table 2), undiluted smoke ageing within 
the first holding vessel (0, 3 and 10 minutes) and diluted smoke ageing within the first holding 
bag (0, 3, 6, 10, and 15 minutes). To minimise variance, we conducted all initial tests using 
Coresta Monitor No. 6 cigarettes (CM6), which is a non-commercial maximal homogenised 
research cigarette from a certified batch. Smoking regimes were also tested on Phillip Morris 
One cigarettes (PhM1).  
 
Table 1. Smoking conditions for different smoke measurements. 
 Cigarette Puff # Regime Dilution Puff to measurement 
Puff  number 
 
CM6 
 
2,4,6,8,10 
 
ISO 3308 
 
77,143 
 
45 seconds 
 
Regime (CM6) 
 
CM6 
 
6 
 
Canadian with and w/o 
tape., ISO #5 and 3308 
77,143 and 
98,182 
45 seconds 
 
Regime (PhM1) 
 
PhM1 
 
6 
 
Canadian with and w/o 
tape, ISO 3308 
77,143 and 
98,182 
45 seconds 
 
Glass ageing (undiluted) 
 
CM6 
 
6 
 
ISO 3308 
 
77,143 
 
+ 0, 2, 9 minutes 
 
Bag ageing (diluted) 
 
CM6 
 
6 
 
ISO 3308 
 
77,143 
 
+ 0, 2, 5, 9, 14 minutes 
 
Brands (10 mg tar) 
 
Camel, Lucky Strike, L&M 
Marlboro, and Pall Mall. 
6 
 
ISO 3308 
 
77,143 
 
45 seconds 
 
Types #1 
 
CM6 and PhM1 
 
6 
 
Canadian tape 
 
77,143 
 
45 seconds 
 
Types #2 
 
Marlboro Red and Gold,  
and PhM1 
6 
 
ISO 3308 
 
77,143 
 
45 seconds 
 
 
Table 2. Applied smoking regimes by the Cerulean SM-450 smoking machine. 
 
We first validated our method by making ten measurements of five cigarette brands, each with 
10 mg tar and 0.8 mg nicotine displayed on the cigarette pack (1 mg variation in both true 
yields allowed): Marlboro, L&M, Camel, Pall Mall and Lucky Strike. Next, we used our 
method to analyse three cigarettes types with different tar values, manufactured by Philip 
Morris: Marlboro Red (10 mg regular-tar/full blend), Marlboro Gold (7 mg low-tar) and the 
high-ventilated filter cigarette Philip Morris One (1 mg ultralow-tar). For further validation, 
we calculated tar mass per cigarette for these three types. All cigarettes were purchased in the 
Netherlands in 2009. 
 
 
Method ISO 
3308 
Modified ISO 
#5 
Canadian 
Intense 
Modified 
Canadian 
Application Area International N.A. International N.A. 
Puff Volume (cm
3
) 35 35 55 55 
Puff Frequency (min
-1
) 1 1 2 2 
Puff Duration (s) 2 5 2 2 
Tape (vent blocking %) No No Yes (100%) No 
N.A: Not applicated. 
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Setup: smoking, sampling and measuring 
Figure 1: Cigarette smoke was produced by a Cerulean SM 450 smoking machine conforming 
to ISO standards, with electric ignition and cigarette conditioning at 22 °C and a relative 
humidity of 60%. Mainstream smoke sampling was conducted using cascaded dilution in 
order to create both a substantial measurement volume and a measurable concentration range. 
We collected generated smoke per single puff in a 190 ml ellipsoidal glass holding vessel 
filled with filtered air and with indentations in the glass to create turbulence for 
homogenisation (step 1). We diluted the whole puff sample (35 or 55 ml, depending on puff 
volume) within 5 seconds by transporting 6 litres of filtered air through the vessel and 
subsequently collecting the homogenised sample in a 10 litre octagonal Tedlar® bag (step 2). 
This produced first dilution factors of 171 (6,000/35) and 109 (6,000/55). At 15 seconds, we 
sampled another 10 or 20 ml of the dilutions into another glass vessel – depending on the 
initial puff volume – transported 9 litres of filtered air through the vessel and collected the 
final dilution into a second 10 litre Tedlar® bag, thus producing final samples with dilution 
factors of 77,143 for 35 ml puffs and 98,182 for 55 ml puffs (step 3). 
 
Figure 1. Experimental test formation with Cerulean smoking machine SM450. Connections are by 
carbosilicon tubing.    = valve by polyvinylidene fluoride and polytetrafluoroethylene (Teflon) 
 
 
 
 
 
 
 
 
 
 
 
 
 
We initiated sample measurements at 30 seconds from smoke production using a universal 
optical spectrometer (1.109 aerosol spectrometer, Grimm Aerosol Technik GmbH), with size-
dependent induced laser scattering of particles between 0.25 and 32 µm at a flow rate of 1.2 
l/min, (step 4). Grimm calibration procedures as at 2009 assured an accuracy of ±2%. Though 
we cleaned the setup between measurements through repeated vacuuming and rinsing with 
 
 
Tedlar® bag 2 
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filtered air, we discarded the first two six-second measurements to obtain ten successive valid 
sample distributions from about 45 seconds of smoke production. 
 
Study outcome parameters 
We present size-resolved particle distributions per ml of produced smoke as lognormal size 
distributions: dN/dln(D) – dN equals particle count per volume (ml), dln(D) equals lognormal 
channel size range.
26
 Channel sizes are presented as geometric means: (lower channel limit * 
upper channel limit)
0.5
. We calculated particle mass/cm
3
 per channel, assuming sphericity, and 
determined total tar mass per cigarette as follows: ∑channels(1/6π · Dchannel mean
3
 · ρ · dN) · puff 
volume · total number of puffs. Dchannel mean equals geometric mean diameter and mean tar 
density (ρ) was set at 1 gram/cm3.27 
 
Statistics 
We first evaluated channel sample distributions by Shapiro-Wilk test and variance 
distributions by Levene’s test. We evaluated reproducibility of all channels combined based 
on the mean coefficient of variance (CoV): √(∑sd2/n) / (∑mcpc/n) with sd: standard deviation, 
n: number of channels, mcpc: mean count per channel. 
 
We analysed the (level of) agreement between different sampling conditions, based on mean 
log-normal size distributions, using both two-tailed Pearson correlation analyses and Bland-
Altman modelling. Due to proportional differences, the Bland-Altman 95% confidence 
interval (limits) is based on a logarithmic agreement, and includes the 95% confidence 
intervals of these limits. These reveal over- and underestimation for all channels jointly.
28
 We 
performed analysis of variance (ANOVA), repeated measurements ANOVA and mixed 
modelling to analyse condition differences for count mean diameters, single-channel particle 
counts, and  combined channel counts. We analysed all results using SPSS 16.0. Statistical 
significance was assumed for p-values < 0.05. 
 
 
RESULTS 
Methodological conditions. 
We obtained reproducible particle measurements between 250 and 1,000 nm, encompassing 
11 channels: the CoV for ten runs within a single sample remained below 5%. Larger 
particles, if  present, could not be measured reliably due to the high dilution (results were 
mostly 0) and were therefore discarded. The methodological conditions with the least 
between-sample variation and the best between-condition agreement included ISO method 
3308, puff number 6 and direct collecting, diluting and measuring: total particle count (TPC) 
9.4 x 10
7
 particles/cm
3
, mean count particle diameter (CMD) 470 nm and mean CoV 22% 
(Table 3). 
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Table 3. Condition characteristics and statistics of size-resolved particle distributions. All channels 
between 250 and 1,000 nm by 10 different measurements. 
 TPC CMD (nm) CMD difference$ CoV LOA Correlation 
Puff # 
    #2 
    #4 
    #6 
    #8 
    #10 
 
8.9 x 10
7
 
9.1 x 10
7
 
9.4 x 10
7
 
1.0 x 10
8
 
9.9 x 10
7
 
 
459 (439-479)
 
468 (440-496) 
470 (454-487) 
474 (459-489) 
473 (454-492) 
 
#2 vs. 8 
 
27% 
26% 
22% 
19% 
27% 
 
68% - 179% 
97% - 111% 
.
a
 
83% - 99% 
80% - 111% 
 
0.99* 
1.00* 
.
a
 
1.00* 
1.00* 
Regime (CM6) 
    ISO  #5 
    ISO 3308 
    Canadian w/o tape 
    Canadian with tape 
 
8.3 x 10
7 
9.4 x 10
7 
1.3 x 10
8 
1.2 x 10
8 
 
489 (475-502) 
470 (454-487) 
430 (412-449) 
432 (416-447) 
 
All except 
Canadians 
 
24% 
22% 
32% 
38% 
 
68% - 194% 
.
a
 
22% - 310% 
25% - 297% 
 
0.98* 
.
a
 
0.86* 
0.88* 
Regime (PhM1) 
    ISO 3308 
    Canadian w/o tape 
    Canadian with tape 
 
7.2 x 10
7 
7.9 x 10
7 
1.0 x 10
8 
 
400 (384-416)
 
386 (368-403)
 
432 (414-449)
 
 
All 
 
17% 
25% 
28% 
 
.
a
 
62% - 147% 
9% - 328% 
 
.
a
 
0.98* 
0.95* 
Glass ageing 
    0 minutes 
    2 minutes 
    9 minutes 
 
9.4 x 10
7 
2.0 x 10
7 
6.6 x 10
6 
 
470 (454-487) 
478 (459-496) 
484 (462-505) 
 
None 
 
22% 
27% 
21% 
 
.
a
 
10% - 52% 
4% - 16% 
 
.
a
 
0.97* 
0.94* 
Bag ageing  
    0 minutes 
    2 minutes 
    5 minutes 
    9 minutes 
    14 minutes 
 
8.5 x 10
7 
8.3 x 10
7 
7.9 x 10
7 
7.2 x 10
7 
6.0 x 10
7 
 
478 (457-498) 
473 (452-493) 
468 (447-488) 
462 (440-483) 
452 (426-478) 
 
0 vs. 9 min. 
0 vs. 14 min. 
2 vs. 14 min. 
 
29% 
28% 
26% 
27% 
29% 
 
.
a
 
91% - 119% 
83% - 147% 
81% - 190% 
77% - 304% 
 
.
a
 
1.00* 
0.99* 
0.98* 
0.95* 
Types #1 
    CM6 
    Philip Morris 1 
 
1.2 x 10
8 
1.0 x 10
8
 
 
432 (416-447) 
432 (414-449) 
 
None 
 
38% 
28% 
 
.
a
 
75% - 92% 
 
.
a
 
0.99 * 
TPC: mean total particle count/cm
3
/puff. CMD: count mean diameter (95%-confidence interval). CoV: 
coefficient of variance (%). LOA: limits of agreement, 100% indicates maximum agreement, <100% 
underestimation and >100% overestimation. Correlation between conditions by Pearson’s correlation 
coefficient. 
a
 is redundant; 
$
 ANOVA: p ≤ 0.05; * p ≤ 0.001 
 
 
Whereas puff numbers and diluted smoke ageing revealed only minor differences (Figure 2 
and 3), smoking regime (Figure 4 and 5) and undiluted smoke ageing (Figure 6) appeared to 
be important factors determining changes in size-resolved particle distributions (Table 3). 
Whereas the undiluted samples revealed a rapid TPC decline with a parallel (non-significant) 
increase of CMD (step 1), the diluted samples appeared rather stable during the first minutes 
(step 2). As expected, taping did not significantly influence CM6 smoke yields, but 
substantially affected the high-ventilated filter PhM1 cigarettes. Although we observed a 
significant increase of TPC and decrease of CMD with more intense regimes in general, 
PhM1 revealed an increase of CMD with taping. In addition, the taped PhM1 smoke yields 
were almost similar to the taped CM6 smoke yields.  
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Figure 2. Logarithmic particle size distribution for different sequential puffs (CM6 
cigarettes, ISO 3308 smoking regime, 77,143 dilution and 45 seconds from 
smoking to measurement). Error bar (
┬
) is standard error. 
 
 
Figure 3. Logarithmic particle size distribution for different diluted bag maturation 
times (CM6 cigarettes, 6
th
 puff, ISO 3308 smoking regime and 77,143 dilution). 
Error bar (
┬
) is standard error. 
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Figure 4. CM6 logarithmic particle size distribution for different smoke regimes 
(CM6 cigarettes, 6
th
 puff, 77,143 and 98,182 dilution and 45 seconds from smoking 
to measurement). Error bar (
┬
) is standard error. 
 
 
Figure 5. Logarithmic particle size distribution for different smoke regimes of Philip 
Morris One cigarettes (6
th
 puff, 77,143 and 98,182 dilution and 45 seconds from 
smoking to measurement). Error bar (
┬
) is standard error. 
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Figure 6. Logarithmic particle size distribution for different undiluted maturation 
times (CM6 cigarettes, 6
th
 puff, ISO 3308 smoking regime and 77,143 dilution). 
Error bar (
┬
) is standard error. 
 
 
 
Method utilisation 
Different brands of cigarettes were analysed to validate our method. This revealed that our 
method was fairly reproducible with CoV below 26% (Table 4, table 5, and Figure 7). Our 
analyses of different cigarette types also showed the ability of tar values to reflect size-
resolved particle distributions (Table 4 and Figures 8, 9, and 10).  
 
Figure 7. Logarithmic particle size distribution for different cigarette brands (6
th
 
puff, ISO 3308 smoking regime, 77,143 dilution and 45 seconds from smoking to 
measurement). Error bar (
┬
) is standard error. 
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Table 4. Brand and type characteristics and statistics of size-resolved distributions. All channels 
between 250 and 1,000 nm by 10 different measurements. 
 TPC CMD (nm) CMD Difference
$
 CoV Tar (mg) 
Brands (10 mg tar) 
     Marlboro 
     Lucky Strike 
     Pall Mall 
     Camel 
     L&M 
 
1.0 x 10
8
 
9.4 x 10
7
 
1.1 x 10
8
 
1.4 x 10
8
 
1.1 x 10
8
 
 
467 (456-478) 
451 (429-473) 
460 (442-478) 
449 (436-461) 
452 (429-475) 
 
Marlboro vs. Camel 
 
11% 
22% 
26% 
13% 
23% 
 
.
a 
.
a 
.
a 
.
a 
.
a
 
Types #2 
     Philip Morris One (1 mg tar) 
     Marlboro Gold (7 mg tar) 
     Marlboro Red (10 mg tar) 
 
7.2 x 10
7 
8.1 x 10
7 
1.0 x 10
8
 
 
400 (384-416) 
457 (437-476) 
467 (456-478) 
 
1 vs. 7 mg 
1 vs. 10 mg 
 
17% 
26% 
11% 
 
1.5 
3.0 
3.9 
TPC: mean total particle count/cm
3
/puff. CMD: count mean diameter  (95%-confidence interval). 
$
ANOVA: p 
≤ 0.05. CoV: coefficient of variance (%). Tar: yields per cigarette, calculated from size-resolved particle 
distributions..
a
 is not determined. 
 
Table 5. ANOVA for single-channel particle numbers for different cigarette brands (10 mg tar). 
Channel (nm) 265 289 324 374 424 474 538 614 674 748 894 
Marlboro A A A A A A A A A A A 
Lucky Strike 0.28 0.69 0.95 1.0 0.99 0.73 0.28 0.25 0.36 0.71 0.98 
Pall Mall 0.05 0.13 0.28 0.67 0.96 0.94 1.0 1.0 0.99 0.98 0.90 
Camel 0.00* 0.00* 0.00* 0.00* 0.00* 0.00* 0.08 0.84 0.99 1.0 1.0 
L&M 0.17 0.22 0.37 0.70 0.97 1.0 0.99 0.90 0.85 0.93 0.98 
A
 is redundant; * p value <0.05 
 
The final analyses to investigate the ability of tar yields to reflect size-resolved particle 
distributions in mainstream cigarette smoke revealed very different particle size distributions 
across cigarette types with different tar yields (ultra low-tar cigarettes (PhM1, 1 mg tar), low-
tar (Gold, 7 mg tar) and regular-tar (Red, 10 mg tar)), while ultra low-tar cigarettes 
significantly exhibit the smallest CMD (table 4 and Figure 8). Surprisingly, Figure 9 reveals a 
linear relation between particle size and the ratio between regular-tar and ultralow-tar 
cigarettes. The expected tenfold ratio – based on stated tar yields – was approximated for the 
largest particles only. Below 350 nm, ultralow-tar cigarettes have significantly higher particle 
counts. Figure 10 presents the total calculated size-resolved particle mass for different 
cigarette types. 
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Figure 8. Logarithmic particle size distribution for different cigarette 
types (6
th
 puff, ISO 3308 smoking regime, 77,143 dilution and 45 
seconds from smoking to measurement). 
 
 
Figure 9. Logarithmic ratio of smoke yields Marlboro full blend / Phillip 
Morris One (R
2
 = 0.99, p < 0.01). Error bar (
┬
) is standard error. 
 
 
 
 
 
 
 
 
Figure 10. Estimated size-resolved particle mass for different cigarette 
types (6
th
 puff, ISO 3308 smoking regime, 77,143 dilution and 45 
seconds from smoking to measurement). 
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DISCUSSION 
Key results 
We developed a reproducible and representative method to measure size-resolved particle 
distributions between 250 and 1,000 nm in mainstream cigarette smoke – i.e., smoking regime 
ISO 3308, sixth puff and direct collecting, diluting (1:77,143) and measuring – and observed a 
poor ability of tar values to predict size-resolved particle distributions. In addition, TPCs were 
similar, mainly due to underestimation of small particles in low-tar cigarettes. Blocking of 
filter ventilation holes, however, resulted in a similar particle distribution and particle count 
across cigarettes with different tar yields. 
 
Strengths and limitations 
In order to decrease active sample sedimentation and coagulation due to fabric features and 
overpressure, we used inert Tedlar® bags that could contain a maximum volume of 10 litres 
each. The ellipsoidal vessel and octagonal bag shapes, and transportation of our samples by a 
relatively large flow of filtered air through the whole system diminished line or gravimetric 
losses and homogenised samples via turbulence. As none of the Tedlar® interior walls 
showed any discoloration from cigarette smoke after the experiments, diffusion, gravimetric 
and electrostatic losses seem negligible. Altogether, absolute sample losses were reduced to a 
minimum. Relative sample losses did occur however, mainly due to undiluted ageing effects, 
probably through coagulation. Although we minimised undiluted ageing times, this might 
have caused additional variation, in addition to variation due to cigarette type. This ageing 
process did not particularly affect larger particles, making gravitational settling unlikely. 
Diluted ageing caused minor irrelevant changes only, such as the decreasing CMD due mainly 
to gravitational losses, but did not jeopardise general reliability. Overall, variation in our 
method is comparable to variation in tar values (1 mg variation allowed), and mostly reflects 
variability among cigarettes themselves. 
 
We characterised cigarette smoke yields as tri-modal size-resolved distributions; TPC and 
CMD approximately 1 x 10
8
 particles/ml and 455 nm in 10 mg tar cigarettes (Table 4). Size-
resolved particle distributions have previously been measured through, for example, light 
scattering optical aerosol spectrometry and state-of-the-art electrical mobility spectrometers 
(DMS by Cambustion, SMPS+E by Grimm Aerosol Technik).
24;29
 Compared to previous 
studies, our method shows good reproducibility and confirms that distributions are mainly 
affected by smoking regimes, filter ventilation and undiluted ageing. Studies from the 1980’s 
exhibit the highest TPC (up to 7 x 10
9
 particles/ml) in part due to higher tar yields in tested 
cigarettes of around 40 mg per cigarette.
30-32
 More recent studies reveal 5-10 x 10
8
 
particles/ml.
24;25
 Nevertheless, our TPC appears low whereas our CMD appears high. 
Presumably, this upward shift in particle size and subsequent decrease in particle count 
occurred primarily due to coagulation processes before dilution and within the first second 
after smoke formation.
33
 This shift could further have been caused by our lowest detection 
limit at 250 nm and by potential bias from a reduced detection efficiency at this low end of 
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the detection range (which may have caused the tri-modal distribution). Indeed, our pilot 
study with simultaneous measurements from the same diluted sample using a scanning 
mobility particle sizer seemed to underrate the smallest particles, though appeared similar 
above 400 nm. However, this underrating would be proportional across different cigarettes. 
 
Our method approximates claimed tar values, but seems to underestimate tar yields in regular 
tar cigarettes in particular. Since we were unable to produce valid results for particles with the 
most mass (>1 µm) due to massive dilution, gravitational losses or else by their absence, this 
might explain some of the underestimation. More specifically, particles >1 µm were only 
demonstrated once, which required several dilution steps.
32
 
 
Interpretation 
Smoking causes devastating diseases. Currently, disease-risk is categorised based on tar 
values, which are a poor predictor. Both tobacco industry development and government 
monitoring focus on these values only, which implies an unfortunate prioritisation. Our study 
may help to expose the deceptive nature of current categorisation. Although regional and 
seasonal batch-specific variations restrict generalisation of our results, some general 
observations are possible. Aside from moistening, we believe our dilution cascade more or 
less reflects real-life two-phased smoking patterns – i.e. a short intraoral retention of 
approximately two seconds followed by a relatively stable dilution by inhalation. Factors such 
as puff number and smoking regime were fairly representative for the measured distributions.  
 
As particle mass has a non-linear relation with particle size, particle mass would poorly reflect 
size-resolved particle distributions in cigarette smoke. Indeed, our findings support this thesis. 
Moreover, our findings suggest that particle counts and distributions < 1 µm do not change in 
proportion to the tar values displayed on cigarette packs. In fact, tar values severely 
underestimate particle counts in low and ultra low-tar cigarettes, and of smaller particles in 
particular. These tar measurements are affected by filter ventilation,
6;34
 and our method 
confirms that this appears to effect a similar change in calculated mass yields. As these yields 
were comparable when the vent holes were blocked, filter ventilation appears to be an 
important determinant of particle size-distributions. However, other factors such as porous 
cigarette papers, expanded tobacco and reconstituted tobacco sheet may interfere. In our 
study, filter ventilation seemed to mainly decrease counts of larger particles and increase 
counts of smaller particles. It could be conjectured that this shift is due to dilution via vent 
holes, whether through vaporisation or reduced agglomeration. Alternatively, the decreased 
flow in a filter-ventilated cigarette could cause a shift towards larger particle diameters. A 
comparison with two studies demonstrated an overall decrease of particles with an additional 
shift from small to large particles due to filter ventilation.
24;25
 Anderson and colleagues did 
not observe this diameter shift.
30
 Apparently, the decisive factor in particle shifts can be 
variable. 
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Overall, our study suggests that people who smoke low or ultra low-tar cigarettes are exposed 
to an excess of small particles, which are able to penetrate deeper alveolar regions, have a 
larger reactive surface area per mass, have a capacity for extra-pulmonary translocation and 
thus are potentially more toxic than larger particles.
21;22;35-38
 Vent-blocking would expose 
these smokers to similar smoke yields as smoking regular-tar cigarettes. Therefore, our results 
cast further doubt on the reliability and value of current tar measurements with respect to 
smoke exposure and smoke-related disease. 
 
Conclusions 
We developed a valid, reproducible and fairly representative method to study the ability of tar 
values to represent particle counts of smaller particles in mainstream cigarette smoke. Our 
method revealed that claimed tar values poorly reflect particle counts and size-resolved 
distributions between 250 and 1,000 nm. In particular, smaller particles in lower tar cigarettes 
were underestimated. As these smaller submicron particles contribute little to mass-based tar 
values, but may be more toxic than larger particles, our study supports the view that current 
tar values are poor predictors of disease risk and are deceptive to smokers. We therefore 
support a change in the current characterisation and labelling of cigarette smoke. 
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ABSTRACT 
 
Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease, characterised by 
poorly reversible, obstructive airflow limitation. Alongside other comorbidities, COPD is 
associated with increased morbidity and mortality resulting from cardiovascular disease - 
mainly heart failure and ischemic heart disease. Both diseases share an important risk factor, 
namely, smoking. About 50% of COPD patients are active cigarette smokers. 
 
Bronchodilation is the cornerstone of pharmaceutical treatment for COPD symptoms, and half 
of all COPD patients use long-acting bronchodilating agents. Discussion about these agents is 
currently focusing on the association with overall mortality and morbidity in COPD patients, 
of cardiovascular origin in particular. 
 
Bronchodilation diminishes the hyperinflated state of the lung and facilitates the pulmonary 
deposition of cigarette smoke by deeper inhalation into the smaller airways. Smaller particles, 
as in smoke, tend to penetrate and depose more in these small airways. In addition, 
bronchodilation indeed increases carbon monoxide uptake in the lungs, an important gaseous 
compound of cigarette smoke. Since the number of cigarettes smoked is positively correlated 
to mortality from cardiac events, we therefore hypothesise that chronic bronchodilation 
increases cardiovascular disease and mortality in COPD patients who continue smoking by 
increasing pulmonary retention of pathogenic smoke constituents. Indeed, a recent meta-
analysis is suggestive that long-acting anticholinergics might increase cardiovascular disease 
if patients exceed a certain number of cigarettes smoked. 
 
To demonstrate the fundamental mechanism of this pathogenic interaction we will perform a 
randomised placebo-controlled cross-over trial to investigate the effect of maximum 
bronchodilation on the retention of cigarette smoke constituents. In 40 moderate to severe 
COPD patients we measure the inhaled and exhaled amount of tar and nicotine, as well during 
maximum bronchodilation as during administration of placebo. The fraction of retention of tar 
and nicotine is subsequently calculated for both circumstances and analysed for association 
with bronchodilation. Further observational cohort studies or randomized clinical trials 
designed to monitor cardiovascular events may well evaluate the interaction. Since many 
patients are at risk for this possibly hazardous interaction, its relevance to our society and 
healthcare is potentially great. The implication will be that the urgency to quit smoking is 
intensified. Besides, chronic bronchodilation – specifically long-acting bronchodilators – 
needs to be discouraged in smoking COPD patients that refuse to quit. 
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hronic obstructive pulmonary disease (COPD) is a disease characterised by poorly 
reversible, obstructive airflow limitation caused by inflammation of the lung 
parenchyma. COPD is one of the most prevalent chronic diseases, with a high impact 
on patients` wellbeing and utilisation of healthcare. Moreover, it is a major cause of death.
1
 
Alongside other comorbidities, COPD is associated with increased morbidity and mortality 
resulting from cardiovascular disease - mainly heart failure and ischemic heart disease - which 
increases in relation to the severity of COPD. In fact, COPD patient mortality predominantly 
results from cardiovascular disease rather than from pulmonary disease.
2;3
 Apart from directly 
inducing cardiovascular disease through pulmonary hypertension and secondary pulmonary 
heart disease, both diseases also share an important risk factor, namely, smoking.
4
 A more 
comprehensive approach in which both diseases are regarded as being part of a chronic 
systemic inflammatory syndrome has been proposed. Nevertheless, smoking remains a major 
risk factor.
5 
 
This paper begins with a discussion of this important common risk factor. After first reviving 
an earlier discussion about beta-2-agonist therapy, we turn to address bronchodilation as the 
current mainstay therapy for COPD and its effect on cardiovascular disease. We continue by 
presenting our hypothesis on the interaction between cigarette smoking and bronchodilation in 
COPD patients. To conclude we propose how to test our hypothesis.  
 
Cigarette smoking 
Cigarette smoking is the cause of COPD in over 80% of COPD patients.
1
 About 50% of 
COPD patients are current smokers; the actual quit rate among COPD patients is modest.
6;7
 
An intensive smoking cessation program resulted in a quit rate of only 38% after 3 years.
8
 
Apart from being the main cause of COPD, smoking is also a very important attributable 
factor in vascular endothelial dysfunction, atherosclerosis and cardiovascular disease.
4
 Recent 
findings have confirmed the positive correlation between the number of cigarettes smoked 
and mortality from cardiac events.
9;10
 In terms of disease progression and mortality in COPD 
patients, cessation of cigarette smoking is the main prognostic factor and the only non-
invasive intervention.
10-12
 Smoking cessation furthermore plays an important role in 
preventing the development of cardiovascular disease in COPD patients,
13
 also given that 
smoking is an important prognostic factor in patients with cardiovascular disease.
9
 
 
History of the ongoing debate on bronchodilator safety 
During the early nineties, continuous treatment with beta-2-agonists was related to asthma 
deaths and near-deaths.
14;15
 Around the same time, studies reported a decline in FEV1 
resulting from chronic use of beta-2-agonists in patients with moderate asthma, as well as 
increased bronchial hyperresponsiveness in both asthma and COPD.
16;17
 Anti-inflammatory 
treatment with inhaled corticosteroids appeared to reverse this decline in FEV1.
18
 Discussion 
on maintenance treatment in asthma and COPD was dominated by these adverse outcomes. 
Even though a meta-analysis proved an inverse relation between asthma deaths and beta-2-
C 
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agonists, its emphasis was on anti-inflammatory treatment.
19
 Bronchodilation, especially with 
long-acting agents, was prescribed with caution for anything beyond short-term symptom 
relief. 
 
Mechanisms proposed to explain the adverse outcomes of these agents pointed to a lack of 
anti-inflammatory treatment as a result of their effective depression of symptoms. This would 
in turn result in undertreatment and in progression of the underlying disease in asthmatics, 
rendering patients prone to bronchial hyperresponsiveness to irritants such as tobacco smoke. 
Ever since these findings were presented the advice for treating asthma patients has always 
been to combine continuous use of beta-2-agonists with a corticosteroid. During the nineties, 
but not after, this advice also extended to COPD patients.
20
 Having reached consensus on the 
continuous use of bronchodilators, specifically long-acting agents, for asthma treatment, 
discussion about these agents is currently focusing on general mortality and morbidity in 
COPD patients, on cardiovascular origin in particular. 
 
 
COPD TREATMENT AND CARDIOVASCULAR DISEASE, AN ONGOING 
DISCUSSION 
 
Bronchodilation is the cornerstone of pharmaceutical treatment for COPD symptoms. 
Bronchodilators improve respiratory function, mainly by reducing the patient’s hyperinflated 
state as COPD progresses, thereby improving symptoms like breathlessness and poor exercise 
capacity.
6;21;22
 Treatments tend to use long-acting bronchodilating agents in order to achieve 
maximum improvement; about 50% of patients use these agents.
6
 Patients with frequent 
exacerbations - preferably those with a forced expiratory volume in one second (FEV1) <50% 
- receive additional treatment with inhalation corticosteroids, which decrease the exacerbation 
rate, probably by reducing inflammation of the lung parenchyma and bronchi.
23
 Corticosteroid 
therapy and long-acting bronchodilating agents are currently available combined in a single 
inhaler for more severe cases, and have a clear impact on symptom relief.
24
 Yet despite the 
improvement of symptoms by each treatment, doubts about their - mainly cardiovascular - 
safety have re-emerged over the last decade. Inhalation corticosteroids seem to protect against 
cardiovascular mortality.
25
 However, whereas recent large studies on long-acting 
bronchodilating agents indicate a decrease of cardiovascular disease and mortality, meta-
analyses indicate whether an indifference or an increase.
24;26-29
 The large studies in favour of 
the bronchodilating agents yet allowed the potentially masking use of short-acting agents in 
the control groups and were not designed to monitor cardiovascular events. In addition, only a 
few studies in these meta-analysis were designed to monitor cardiovascular events. Moreover, 
the safety of chronic bronchodilation as well as combination therapy remains questionable, 
and no one has so far been able to shed satisfactory light on this important question. 
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OUR HYPOTHESIS: INTERACTION BETWEEN BRONCHODILATION AND 
SMOKING 
 
Unfortunately, no studies are available at present that examine bronchodilation in COPD 
patients in relation to interaction with their main prognostic factor: smoking. It seems 
plausible however that bronchodilation diminishes the hyperinflated state of the lung, 
improves smoke inhalation and, as a result, increases the pulmonary deposition of cigarette 
smoke. Furthermore, as mentioned above, the number of cigarettes smoked is positively 
correlated to mortality from cardiac events.
9;10
 We therefore hypothesise that bronchodilation 
increases cardiovascular disease and mortality in COPD patients who continue smoking by 
increasing pulmonary retention of pathogenic smoke constituents. Smoking could thus be the 
link explaining the cardiovascular effects of bronchodilation in COPD patients: 
bronchodilation, especially when effected for long periods of time with long-acting agents, 
enhances the cardiovascular effect of smoking in COPD patients. This interaction is a major 
factor to consider during treatment. 
 
So far, several observations suggest such an interaction between bronchodilators and 
smoking. First, bronchodilators facilitate smoke uptake by, as mentioned above, reducing the 
hyperinflated state of the lung and subsequently increasing the inhalation capacity.
6;21;22
 This 
mechanism enables the deeper inhalation of a larger amount of air and thus smoke into the 
smaller airways. In healthy subjects there is a positive relation between increased inhalation – 
a larger amount of air – and smoke retention.30 The positive influence of deeper inhalations is 
as follows: Smaller particles as in pulmonary inhalation drugs tend to penetrate and depose 
more in the peripheral smaller airways.
31
 Smoke specifically consists of these smaller 
particles.
32;33
 Smoke deposition in particular will therefore benefit from bronchodilator 
enhanced deeper inhalation into the smaller airways. Bronchodilation indeed increases carbon 
monoxide uptake in the lungs, an important gaseous compound of cigarette smoke.
34
 
Although this is based on a small study, it resembles the potential of a similar increased 
uptake for smoke particles. These observations sum up to the theory that bronchodilation 
increases cigarette smoke retention in COPD patients, while an increased amount of cigarette 
smoke has been related to increased cardiovascular disease.
9;10
 In other words, the 
cardiovascular effect of smoking would be increased by bronchodilation in COPD patients. 
Finally, a recent meta-analysis is in fact suggestive that long-acting anticholinergics might 
increase cardiovascular disease only if patients exceed a certain number of cigarettes 
smoked.
27
 This indicates a dose-dependent relationship where bronchodilators change 
cardiovascular outcome significantly, when an increase of the absolute amount of smoke 
retention only becomes substantial if the baseline amount is large enough. 
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TESTING OUR HYPOTHESIS; A STUDY SYNOPSIS 
 
To substantiate our hypothesis, our study will begin by focusing on the following key 
question: Does increased respiratory function after administration of a bronchodilator in 
COPD patients who smoke lead to elevated pulmonary retention of the harmful compounds in 
inhaled cigarette smoke and to short-term biological effects associated with cardiovascular 
disease? To demonstrate the fundamental mechanism of interaction we will perform a double-
blinded randomised placebo-controlled cross-over trial to investigate the effect of 
bronchodilation on the retention of certain cigarette smoke constituents, specifically tar. In 40 
moderate to severe smoking COPD patients we measure the inhaled and exhaled amount of 
tar and nicotine, for each patient once during maximum bronchodilation as well as once 
during administration of placebo. Subsequently we calculate the fractions of retention of tar 
and nicotine, our primary outcomes, for both circumstances. These outcomes will be analysed 
for the predicted association with bronchodilation. The accurate estimation of inhaled and 
exhaled smoke amounts, and thereby the indirect calculation of the retention fraction, has 
been reported previously.
30;35
 Simultaneously we investigate the parallel relation between 
smoke retention and smoking pattern, expressed by the smoke inhalation time and volume, 
measured real-time by the Lifeshirt®.
30;35
 This relation distinguishes whether a larger and/or a 
deeper inhalation of smoke causes the supposed increased retention of smoke by 
bronchodilation. 
 
As we expect a corresponding short-term rise of inflammatory biomarkers in reaction 
to cigarette smoke, that reflect a certain risk on developing cardiovascular disease, we 
presume an increased rise due to bronchodilating induced retention of cigarette smoke. We 
will therefore also study the immediate effect of smoke retention on the levels of selected 
biomarkers by taking successive venous blood samples. This selection is according to 
biomarkers associated with both cigarette smoke and with an increased risk of cardiovascular 
disease.
36;37
 The concentration of these biomarkers, indicative of a potential risk for 
cardiovascular disease, will be analysed for association with bronchodilation as well. 
 
RESUME 
 
COPD is a highly prevalent disease. About 50% of COPD patients are active cigarette 
smokers. Bronchodilation is the cornerstone of pharmaceutical treatment, and half of all 
COPD patients use long-acting bronchodilating agents. However, the impact of these agents 
on mortality and, specifically, on cardiovascular disease, is uncertain. We hypothesise an 
important pathogenic interaction between cigarette smoking and bronchodilation. Since many 
patients are at risk for this possibly hazardous interaction, its relevance to our society and 
healthcare is potentially great. It implies that for at least 25% of all COPD patients the 
bronchodilating treatment method would be at stake. Another implication is that the urgency 
to quit smoking would be intensified. 
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ABSTRACT 
 
Background. Smoking and bronchodilator treatment are both extensively studied as key 
elements in COPD patients. However, little is known about whether or not these elements 
interact in terms of developing cardiovascular diseases in patients with COPD. 
 
Objectives. To explore to what extent the risk of developing ischemic cardiovascular disease 
in COPD patients is mediated by smoking status, use of bronchodilators and - specifically - 
their interaction. 
 
Methods. We performed an observational pilot study on a relatively healthy Dutch COPD 
cohort from a primary care diagnostic centre database with full information on spirometry 
tests, smoking status, bronchodilator use, and other prescribed medication. We defined first 
ischemic cardiovascular events as primary outcome, measured by first prescription of anti-
platelet drugs and/or nitrates. Unadjusted analyses by Kaplan-Meier was followed by adjusted 
Cox’ proportional hazards. 
 
Results. 845 COPD patients, comprising 2,169 observation years, were included in the 
analyses. We observed an increased risk for non-fatal ischemic cardiovascular events by 
smoking (adjusted HR=3.58, p=0.001) and a protective effect by bronchodilators (adjusted 
HR=0.43, p=0.01). Although the protective effect by bronchodilators appears substantially 
minimized in patients that persist in smoking, we could not statistically confirm a hazardous 
interaction between bronchodilators and smoking (HR 2.50, p= 0.21). 
 
Conclusion. Our study reveals bronchodilators may protect for ischemic cardiovascular 
events in a relatively “healthy” COPD population. We did not confirm a hazardous interaction 
between bronchodilators and smoking, although we observed current smokers benefit 
substantially less from the protective effect of bronchodilators. 
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hronic obstructive pulmonary disease (COPD) is a highly prevalent chronic condition 
that is characterised by poorly reversible, obstructive airflow limitation.
1
 This disease 
is caused by cigarette smoking in over 80% of patients.
1
 COPD is associated with 
increased morbidity and mortality, an essential part of which is due to cardiovascular disease, 
mainly ischemic (heart) disease and heart failure, arrhythmias to a lesser degree.
1-4
 
 
The cornerstone of pharmacological treatment of COPD symptoms is bronchodilation. About 
50% of patients with COPD use long-acting bronchodilators, to achieve maximum airway 
dilatation.
5
 Although these agents improve symptoms, recently doubt re-emerged concerning 
their safety, especially in terms of cardiovascular conditions. Whereas large trials on the long-
term effects of long-acting bronchodilators indicate a decrease of cardiovascular disease and 
mortality, meta-analyses suggest an increase.
6-9
  
 
As (the amount of) smoke exposure is positively related to cardiovascular mortality 
10-13
, 
smoking cessation is essential in preventing development or worsening of cardiovascular 
disease in COPD patients.
11,12,14
 Despite smoking cessation programs, approximately 50% of 
COPD patients continue to smoke.
5,15
 Although the effects of smoking and bronchodilators on 
mortality in COPD patients have been studied extensively, their interaction surprisingly 
remained virginally untouched.  
 
We recently hypothesised that a hazardous interaction between (chronic use of) 
bronchodilators and continued smoking could be the missing link in the discussion about 
bronchodilator safety.
16
 Bronchodilators diminish the hyperinflated state of the lungs thus 
increasing air volume displacement and lung ventilation.
5,17
 This may well result in 
enhancement of tobacco smoke inhalation and, as a result, pulmonary deposition of harmful 
cigarette smoke constituents and hence an increase of cardiovascular risk. A report which 
demonstrated that the protective effect of tiotropium bromide on mortality appeared to be 
significant only in non-smokers indirectly supports this hypothesis.
18
 If an interaction between 
smoking and bronchodilator treatment does indeed exist, it could have a substantial impact on 
the pharmacotherapeutic management of patients with COPD who persevere in cigarette 
smoking.  
 
Our aim is to study to what extent the risk of developing cardiovascular disease in patients 
with COPD is mediated by smoking status, use of bronchodilators and - specifically - their 
interaction. In this paper, we investigated our hypothesis by conducting an explorative 
observational cohort study using a primary care pulmonary function database. The current 
study precedes an (ongoing) randomised controlled experiment, where we expose COPD 
patients who are current smokers to cigarette smoke during undilated and maximal 
bronchodilated conditions (www. clinicaltrials.gov, ID: NCT00981851). 
 
 
C 
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METHODS 
Study design 
We conducted an observational cohort study on patients with COPD, who were 
retrospectively selected and followed from a prospectively designed de-identified database 
from a Dutch primary care diagnostic centre that supports general practitioners’ diagnosis and 
monitoring of patients with COPD. The database encloses information as single records per 
yearly visit from 2001 to 2009, and includes spirometry tests, demographic information and 
questionnaires that concern smoking, respiratory symptoms, pulmonary medication, and all 
prescribed co-medication (table 1).
19
 We defined new prescriptions for specific cardiovascular 
medication (see below) as a surrogate outcome marker for non-fatal ischemic cardiovascular 
events. Based on dichotomous current cigarette smoking and current bronchodilator status 
four key study groups were defined. Current non-smokers included both never and former 
smokers, whereas a positive bronchodilator treatment was defined as short-acting (salbutamol, 
fenoterol, ipratropium, terbutaline) and/or long-acting treatment (salmeterol, formoterol, 
tiotropium). 
 
Table 1. Available data from primary care database, measured each visit. 
General characteristics 
 Age 
 Sex 
 Visit 
 
 Total follow up 
Date of birth (dd/mm/yyyy) 
Male/Female 
Sequential number 
Date (dd/mm/yyyy) 
Visit of inclusion until last visit (months) 
Questionnaires 
 Symptoms 
 
 Medication 
 
 Smoking 
MRC dyspnoea scale (score 1-5) 
Exacerbations / rescue medication (yes/no) 
Pulmonary medication (name, dosage, form) 
Co-medication (name, dosage) 
Status (yes/never/quit) 
History (packyears) 
Current cigarette amount per day 
Measurements 
 BMI 
 
 Pulmonary function (by spirometry) 
Length (cm) 
Weight (kg) 
FEV1 pre- and post bronchodilation (ml) 
FVC pre- and post bronchodilation (ml) 
 
Ethics approval 
The medical ethics review board of the Radboud University Nijmegen Medical Centre (CMO 
Region Arnhem-Nijmegen) granted exemption of regular medical ethics review for this 
database analysis. The Dutch Data Protection Authority 
(http://www.dutchdpa.nl/Pages/en_ind_cbp.aspx) judged that the use of these de-identified 
data for scientific research is in compliance with acts that regulate the use of personal data in 
the Netherlands. Hence, we did not needed informed consent.  
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Subjects 
We selected all COPD patients according to current GOLD criteria,
1
 without an asthmatic 
component – i.e. ≥ 10% post-bronchodilator reversibility of predicted value of FEV1 – and 
aged over forty years (table 2). At least one subsequent visit to the diagnostic centre was 
required for follow-up. Once selection criteria were met was regarded as inclusion visit. 
Individual follow-up time was considered as the period between study entrance and the last 
available visit. Patients with any co-medication at baseline were excluded to eliminate bias by 
registration errors due to extensive medication lists. We excluded patients with missing data 
on bronchodilators, co-medication or smoking status. Baseline characteristics included 
smoking status, bronchodilator use, age, sex, and COPD severity markers (FEV1 percentage 
of predicted (FEV1%), Medical Research Council (MRC) scores,
20
 and Body-Mass Index 
(BMI)).  
 
Table 2. Criteria to select patients with COPD from our database.  
Inclusion criteria 
 Chronic respiratory symptoms 
 Post-bronchodilation FEV1/FVC < 0.70 
 Post-bronchodilation FEV1 < 100% of predicted value 
 Age ≥ 40 years 
 Follow-up ≥ 2 visits 
 Documented pulmonary and co-medication 
 Documented smoking status 
Exclusion criteria 
 < 10 minutes between pre- and post-bronchodilation measurement 
 ≥ 10% reversibility of predicted value after inhalation of 400 mcg aerosolized salbutamol 
 Cardiovascular medication at baseline 
 Other co-medication at baseline 
 
Outcomes 
We studied first non-fatal ischemic cardiovascular events (including stroke) as our primary 
outcome. We assessed these events by first-ever prescriptions of either anti-platelet therapy 
and/or nitrates (table 3) as surrogates for the actual events, as these are lifelong obligatory 
drugs in the Netherlands in the secondary prevention of ischemic cardiovascular conditions – 
according to Dutch guidelines for treatment of cardiovascular diseases.
21-23
  
 
Table 3. Predefined medication list as surrogate markers for ischemic cardiovascular disease. 
Category Generic drug name Brand name (Dutch) 
 Anti-platelet therapy Carbasalate Calcium 
Acetylsalicylic Acid 
Clopidogrel 
Dipyridamol 
Acetyls./Dipyridamol 
Ascal 
Aspirin 
Plavix / Iscover 
Persantin 
Asasantin 
 Nitrates Nitroglycerine Nitrolingual 
Isosorbidedinitrate 
Isosorbidemononitrate 
Cedocard / Isordil 
Monocard / Promocard 
3.2 
60 
 
Statistical methods 
We analysed the potential effect of bronchodilators and smoking on cardiovascular disease by 
unadjusted Kaplan-Meier analysis first. Next, we performed adjusted survival analysis to 
assess their possible interaction by Cox’ proportional hazard modelling by SPSS 16.0. We 
build our model by backward stepwise likelihood ratio of all available baseline confounders 
as suggested by literature (age, smoking, sex, GOLD stage, FEV1%, inhaled corticosteroids, 
MRC score, and BMI). The basic model was complemented by smoking status, 
bronchodilator status, and their interaction-term. A HR > 1 of this interaction-term implies 
bronchodilators and smoking interact hazardously. Never and former smokers were also 
analysed separately, to test if these subgroups could be grouped together as current non-
smokers. In addition, we tested the adjusted effect of bronchodilators in both the current 
smokers and the current non-smokers. Statistical significance of hazard rates was set at a p-
value of <0.05. Our null-hypothesis is: there is no (interactive) effect by smoking and 
bronchodilators on cardiovascular disease. To validate the surrogate definitions, we compared 
the incidence of ischemic cardiovascular events with those published in other studies. 
 
Figure 1. Selection of records and patients for analysis to establish risk on cardiovascular disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
±30.000 patients (44.921 records) 
assessed for eligibility 
 
1.740 patients (5.397 records) 
recruited 
 
575 patients (1727 records) 
had surrogate marker at baseline and 
were excluded 
 
845 patients (2692 records) 
 included for analyses 
 
28.260 patients (39.524 records) 
did not meet entry criteria and were 
excluded 
127 patients: 
No current smoking 
or bronchodilator 
 
299 patients: 
No current smoking 
Current 
bronchodilator 
 
140 patients: 
Current smoking 
No bronchodilator 
 
279 patients: 
Current smoking and 
bronchodilator 
Selection criteria were based on age ≥ 40 years, FER < 0.70, FEV1 < 100% of predicted, 
reversibility test > 10 minutes after primary test, reversibility < 10% of predicted, availability of 
smoking status, bronchodilators and co-medication, and ≥ 2 visits. 
 
320 patients (978 records) 
had other co-medication at baseline 
and were excluded 
 
61 
 
RESULTS 
Population characteristics 
The database contained 44,921 records, representing about 30,000 patients. Patient selection 
(figure 1) resulted in recruitment of 1,740 patients. Our surrogate marker revealed an ischemic 
cardiovascular disease prevalence of 15.0% (261 patients) with a subsequent incidence of 
4.6% ischemic cardiovascular events (200 events together) in this general COPD population. 
After exclusion of patients with baseline co-medication, the study sample consisted of 845 
patients (table 4): 95 never-smokers, 331 former smokers and 419 smokers with an average 
follow-up of 31 months and 3.2 follow-ups, comprising 2,169 patientyears and 2692 follow-
ups. Together they showed a yearly incidence of 1.8% first ischemic events (38 events 
together). Apart from differences in the rate of ischemic events, group differences particularly 
are based on sex, age and use of inhaled corticosteroids. The unadjusted figures of table 4 
show that ischemic event rates were higher in smokers (regardless of bronchodilator use) and 
in patients that did not use bronchodilators (regardless of smoking status). 
 
 
Table 4. Characteristics of baseline study sample (845 patients), based on four key study groups. Data 
are n (%) or mean (±SD) 
 Baseline non-smokers Baseline smokers 
Bronchodilator use No (n=127) Yes (n=299) No (n=140) Yes (n=279) 
Demographics 
Age (years) # 
 
62 (±10.0) 
 
61 (±10.9) 
 
58  (±8.3) 
 
57  (±9.8) 
Sex (male) # 88 (69%) 183 (61%) 93 (66%) 142 (51%) 
Severity markers 
FEV1%predicted post BD 
 
72% (±13.5) 
 
71% (±15.1) 
 
71% (±15.1) 
 
70% (±14.8) 
MRC score (0-5) 1.6 (±0.9) 1.7 (±0.9) 1.7   (±0.9) 1.8    (±0.9) 
Pulmonary medication 
Long-acting BD use # 
 
- 
 
202 (68%) 
 
- 
 
161 (58%) 
Short-acting BD use # - 150 (50%) - 168 (60%) 
Inhaled corticosteroids # 20 (16%) 217 (73%) 15 (11%) 164 (59%) 
Outcome characteristics 
Mean follow-up (yrs) 
 
30.3 (±19.8) 
 
31.8 (±19.0) 
 
29.4 (±18.7) 
 
30.7 (±19.6) 
Ischemic events# 7 (5.5%) 4 (1.3%) 12 (8.6%) 15 (5.4%) 
Time to event (months)* 26.9 (±15.9) 39.5 (±28.5) 29.8 (±18.8) 33.1 (±17.4) 
# significant difference between groups (p < 0.05); * based on patients with an event; BD = Bronchodilator. 
 
 
Statistical analyses of smoking and bronchodilator interaction 
Unadjusted analyses of smoking and bronchodilators (figure 2) as single factors for ischemic 
cardiovascular events by Kaplan-Meier revealed a hazardous and protective effect, 
respectively (both Log-Rank tests p < 0.01). Backward stepwise analysis to select 
confounders for adjusted interaction analyses, showed age (HR = 1.08 (CI 1.04 – 1.12), p < 
0.001), smoking (HR = 3.58 (CI 1.73 – 7.42), p = 0.001) and bronchodilators (HR = 0.43 (CI 
0.23 – 0.82), p = 0.01) as significant predictors of ischemic cardiovascular events. As there 
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was no significant difference between never and former smokers, these groups could be 
pooled together as current non-smokers. The null-hypothesis on interaction was not rejected: 
survival analysis (table 5) did not reveal a clear trend on hazardous interaction: 
bronchodilators HR = 0.23 (CI 0.07 – 0.77), p = 0.02 and interaction HR = 2.50 (CI 0.59 – 
10.63, p = 0.21). However, a statistically significant age-adjusted protective effect of 
bronchodilators was observed in non-smokers, whereas the effect was much smaller and 
insignificant in smokers: non-smokers HR = 0.22 (CI 0.06 – 0.76, p = 0.02), smokers HR = 
0.58 (CI 0.27 – 1.24, p = 0.16). 
 
 
Table 5. Hazard ratios for ischemic cardiovascular events in our subgroup without co-medication at 
baseline. Hazard ratio < 1 indicates a protective effect. 
 HR 95%-CI P value 
Age (per year) 
Smoking 
Bronchodilator use 
Smoking * BD interaction 
1.08 
2.32 
0.23 
2.50 
1.04 – 1.11 
0.89 – 6.07 
0.07 – 0.77 
0.59 – 10.63 
<0.001 
0.09 
0.02 
0.21 
HR = hazard ratio; CI = confidence interval; BD = Bronchodilator 
 
 
 
Figure 2. Kaplan-Meier chart that shows the effect of bronchodilators on non-fatal ischemic 
cardiovascular events for all 845 patients, including current smokers and current non-smokers (Log-
Rank test p < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
___ With bronchodilator 
----- Without bronchodilator 
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DISCUSSION 
Our aim was to explore to what extent the risk of developing cardiovascular disease in 
patients with COPD is mediated by smoking status, use of bronchodilators and - specifically - 
their interaction. This pilot study shows smoking increases the risk to develop cardiovascular 
disease in relatively “healthy” COPD patients (HR 3.58, p= 0.001) whereas bronchodilators 
may be protective (HR 0.43, p= 0.01). Although the protective effect by bronchodilators 
appears substantially minimized in patients that persist in smoking, we could not statistically 
confirm a hazardous interaction between bronchodilators and smoking (HR 2.50, p= 0.21). 
 
Strengths and limitations  
Although our design restricted us to relatively “healthy” COPD patients without an asthmatic 
component by spirometry, we were able to include a substantial number of primary care 
COPD patients in our analyses (n=845). Nonetheless, the percentage of eligible patients 
selected for analyses was relatively small. Most patients failed inclusion in our study sample 
because they did not have any follow-up visits, i.e. they did not enter the diagnostic centre’s 
monitoring service (due to no confirmation of any pulmonary disease or due to non-
compliance), and/or they did not meet the GOLD criteria for COPD.
1
 A non-fatal ischemic 
cardiovascular event is not necessarily a reason to withhold a patient from further pulmonary 
follow-up and therefore would not present a large source of bias due to selective dropout from 
the study population. The power of our study is limited by the relative short follow-up of 2.5 
years per patient and a relative long interval of usually 1 year between monitoring visits, 
which limits our ability to pinpoint the actual cardiovascular event to the specific date on 
which it occurred. Moreover, as patients gather substantial cardiovascular risk during their 
lifetime, an additive risk during follow-up based on interaction between bronchodilators and 
smoking would be relatively small. 
 
Bias results in part from patient dynamics before and during the observation period, mainly 
due to a change of smoking and/or bronchodilator status. The cardiovascular risk of former-
smokers approximates the level of never-smokers rapidly,
11,12,14
 and hence these groups could 
be combined into a composite “current non-smokers” group. Although former smokers 
specifically are prone to change of smoking habit, separate analyses did not reveal a 
significant difference in cardiovascular risk between former and never smokers, and both 
showed a significantly lower risk compared to current smokers.  
 
Other potential sources of bias may result from our surrogate marker, registration errors and 
confounders other than the ones available in our dataset – i.e., hypertension, diabetes and 
heredity. The incapacity to adjust for hypertension and diabetes is somewhat counteracted due 
to its high correlation with age, smoking and BMI, confounders we did adjust for. 
Furthermore, our relatively healthy population did not use any other medication and hence 
hypertension and diabetes, if present, would be only mild. Next, registration errors were 
reduced by excluding patients with missing data on co-medication and by excluding patients 
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with co-medication at baseline. Finally, our choice to use prescribed medication as surrogate 
markers for cardiovascular events warrants reflection. We based our primary outcome on anti-
platelet therapy and nitrates. Dutch guidelines do not recommend these drugs for primary 
prevention, whereas they are clearly indicated for lifelong secondary prevention and 
symptomatic treatment, respectively.
21,22 
Indeed, a recent Dutch study observed anti-platelet 
prescriptions in approximately 90% of patients, 3 years after myocardial infarction.
24
 In 
addition, other indications for these drugs by Dutch prescription regulations are rare.
23
 Hence, 
the possible bias from not prescribing our listed medication after an event, only prescribing 
temporary or prescribing for other diseases than our outcome – like hypertension –, seems 
negligible. We therefore assume a high sensitivity and specificity for this surrogate outcome 
definition to actually reflect our primary outcome, i.e. ischemic cardiovascular events.  
 
Validation 
Our design resulted in a selection of relatively “healthy” COPD patients without important co-
morbidity that are compliant with a primary care monitoring service. Hence, these patients 
would have less cardiovascular events, and translation of our results to the general COPD 
population with more risk of cardiovascular disease and (overruling) co-morbidity tends to be 
difficult. To validate our method (i.e., prescriptions for secondary prevention of ischemic 
cardiovascular disease), we compared our results with the cardiovascular incidence of other 
studies. Incidence of (mainly non-fatal) ischemic cardiovascular events in COPD populations 
is reported as 1.7%.
24
 Our recruited population therefore reveals a large overestimation at 
first, probably due to registration errors. The 1.8% incidence of our final study sample 
improves validity, but may still somewhat overestimate incidence, since we did not register 
fatal events and since our study sample is relatively healthy. Furthermore, our effect sizes of 
known risk factors – age and smoking – are comparable to other studies.10-13 Altogether, we 
appreciate our markers as surrogate for outcome of ischemic cardiovascular disease as valid. 
 
Interpretation 
Several studies so far reported different findings on the cardiovascular effect of 
bronchodilators in COPD patients.
6-9
 Our hypothesis could explain these differences and 
would enable guidelines to tailor treatment for individual patients more accurately.
16
 
Although this pilot study does not statistically confirm our hypothesis on hazardous 
interaction, possibly due to a lack of power in these “healthy” COPD patients, current non-
smokers seem to benefit more from the protective effect of bronchodilators than current 
smokers with regards to ischemic cardiovascular disease. The large UPLIFT trial 
demonstrates bronchodilative protection depends on smoking status similarly.
18
 We believe 
this substantial minimization of the protective effect of bronchodilators in current smokers 
implies the existence of an interaction, although the extent still remains to be established. 
Although our study was restricted to non-fatal events, we assume a similar effect for 
mortality. Apart from the interaction, we assume bronchodilators themselves might protect for 
ischemic cardiovascular disease by both a suppressive effect on systemic inflammation and 
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improvement of blood oxygenation that stimulates exercise and reduces cardiac stress. An 
alternative explanation is embedded in the causal relation between bronchodilators and 
cardiovascular outcome: patients taking medication could implicate merely good adherence, a 
healthier attitude and therefore fewer events.
26
 However, as our study did not reveal true 
adherence, patients receiving treatment would be generally sicker. 
 
Recommendations 
We suggest that future prescription of bronchodilators for COPD patients that persevere in 
their smoking habit needs more consideration. Since our pilot study is explorative only it does 
not resolve the discussion on bronchodilators. In order to further explore this issue, we 
propose to first study the basic interaction between bronchodilators and smoking. A 
randomised controlled trial to document the possible pathologic mechanism on pulmonary 
smoke retention is currently in progress.
27
 In addition, we recommend to distinguish between 
bronchodilator types and COPD phenotypes as these facilitate various pathways for 
interaction. Different bronchodilators act differently at different pulmonary regions. Accurate 
classification of phenotypes is subject to current discussion.
28
 Finally, we suggest to study a 
more general COPD population and to study cardiovascular diseases other than ischemic. 
 
In conclusion, this explorative study of  relatively “healthy” COPD patients supports a strong 
increased risk on non-fatal ischemic cardiovascular events due to smoking, whereas 
bronchodilators may be moderately protective. We did not confirm a hazardous interaction 
between bronchodilators and smoking, although we observed current smokers benefit 
substantially less from the protective effect of bronchodilators. We recommend to further 
study the safety of bronchodilators in COPD patients that persist in smoking. 
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ABSTRACT 
 
Background. Chronic obstructive pulmonary disease (COPD) is a common disease, 
associated with cardiovascular disease. Many patients use (long-acting) bronchodilators, 
whilst they continue smoking alongside. We hypothesised an interaction between 
bronchodilators and smoking that enhances smoke exposure, and hence cardiovascular 
disease. In this paper, we report our study protocol that explores the fundamental interaction, 
i.e. smoke retention. 
  
Method. The design consists of a double-blinded, placebo-controlled, randomised crossover 
trial, in which 40 COPD patients smoke cigarettes during both undilated and maximal 
bronchodilated conditions. Our primary outcome is the retention of cigarette smoke, 
expressed as tar and nicotine weight. The inhaled tar weights are calculated from the 
correlated extracted nicotine weights in cigarette filters, whereas the exhaled weights are 
collected on Cambridge filters. We established the inhaled weight calculations by a pilot 
study, that included paired measurements from several smoking regimes. Our study protocol 
is approved by the local accredited medical review ethics committee. 
  
Discussion. Our study is currently in progress. The pilot study revealed valid equations for 
inhaled tar and nicotine, with an R
2
 of 0,82 and 0,74 (p< 0,01), respectively. We developed a 
method to study pulmonary smoke retentions in COPD patients under the influence of 
bronchodilation which may affect smoking-related disease. This trial will provide 
fundamental knowledge about the (cardiovascular) safety of bronchodilators in patients with 
COPD who persist in their habit of cigarette smoking.  
 
Trial registration. www.clinicaltrials.gov NCT00981851. 
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hronic obstructive pulmonary disease (COPD) is a common chronic disease, 
characterised by poorly reversible and progressive airflow obstruction. A substantial 
fraction of COPD-related mortality and morbidity is due to cardiovascular disease.
1-3
 
Both diseases share an important risk factor: smoking. Cigarette smoking causes over 80% of 
COPD, whereas 20% of cardiovascular mortality is attributable to smoking.
4-6
 Cessation of 
cigarette smoking is an important prognostic factor in patients with COPD and cardiovascular 
disease. Besides, smoking cessation is essential in preventing development of cardiovascular 
disease in all people, including COPD patients. However, half of COPD patients are persistent 
smokers.
4,5,7-9
  
 
Meanwhile, the cornerstone of pharmaceutical treatment of COPD symptoms is 
bronchodilation. It seems rational however, that bronchodilation diminishes the hyperinflated 
state of the lung, enhances deeper smoke inhalation and as a result increases the pulmonary 
deposition or uptake of pathogenic cigarette smoke constituents. Concurrently, the amount of 
cigarettes smoked – i.e. the amount of smoke - is related positively to cardiac mortality.4,5,10 
Therefore, we hypothesised a hazardous interaction between chronic bronchodilation and 
smoking, that would result in increased cardiovascular morbidity and mortality in COPD 
patients who persevere in smoking.
11
 If the hypothesized interaction does indeed exist, the 
consequences in terms of pharmacotherapeutic management of patients with COPD would be 
substantial. However, no strong evidence to substantiate our hypothesis has been published 
yet. With the randomised controlled trial described in this paper we aim to expose the 
fundamental mechanism of interaction. Similar studies on smoke retention in general have 
been reported, but not in relation to bronchodilator treatment or in patients with COPD.
12-15
 
 
Our first objective is essentially to demonstrate a proof of concept of the fundamental 
underlying assumption: does administration of a bronchodilator to a patient with COPD lead 
to increased retention of cigarette smoke constituents. In this article we describe the design 
and methods of our study that determines the effect of bronchodilation on smoke retention in 
COPD patients when they smoke a cigarette. In addition, we determine the effect of 
bronchodilation on smoking patterns and short-term biological effects associated with 
cardiovascular disease. Apart from our methods, we report the results of our pilot study that 
validated the retention measurements. 
 
 
METHODS 
Interaction in COPD experiment (ICE) is a randomised trial designed to evaluate the effect of 
bronchodilators on smoke retention in COPD patients. 
 
Study design 
The study is designed as a double-blinded, placebo-controlled, randomised crossover trial, in 
which 40 COPD patients – who are current smokers – smoke a cigarette under controlled 
C 
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conditions, both during undilated and maximal bronchodilated conditions during two separate 
sessions. Participants have a ‘wash-out’ period of 1 week between both sessions and the 
experiment always initiates between 8:00 and 9:00 AM. The study is registered at 
www.clinicaltrials.gov identification number NCT00981851. 
 
Interventions 
After inclusion, patients are randomly allocated to commence with one of both bronchodilated 
conditions. During one session, participants smoke a first cigarette, have their medication 
administered directly after, and 45 minutes later they smoke their second cigarette. 
 
 Bronchodilation. To accomplish both bronchodilated conditions, patients receive either a 
combination of potent bronchodilating drugs – 5 µg tiotropiumbromide dry powder 
inhalation by Respimat as well as 400 µg aerosolized salbutamol by volume spacer – or a 
combination of their placebos. These bronchodilators ensure a gradual and maximal 
bronchodilation after 45 minutes and both offer similar placebos.
16,17
 In order to initiate 
the experiment undilated, patients have to refrain from bronchodilators according to table 
1. Patients are allowed short-acting bronchodilators up to 8 hours before the experiment to 
minimise bronchodilator withdrawal. To minimise intra-individual variation in baseline 
bronchoconstriction, patients should not have had an exacerbation or have used more than 
usual short-acting rescue medication within the previous week.  
 
Table 1: Duration of bronchodilator abstinence 
8 hours  Salbutamol 
 Terbutaline 
 Ipratropium bromide 
24 hours  Formoterol 
 Salmeterol  
48 hours  Tiotropium bromide 
 
 Smoking. Smoking occurs according to well controlled protocols. To neutralise the effect 
on smoking patterns by nicotine craving, tobacco smoking is accepted up to 8 hours 
before the experiment and patients have a cigarette prior to medication administration. 
During all study sessions patients smoke CM6 cigarettes, a non-commercial cigarette with 
relatively little variation in smoke yields.
18
 Cigarettes are conditioned at 22°C and at 60% 
relative humidity – according to ISO standards – in an incubator with a saturated mixed 
salt solution.
19
 Cigarettes are ignited electrically. Participants wear a nose-clip, and are 
instructed to inhale all smoke, exhale into a mouthpiece connected to Cambridge filters 
and to smoke the cigarettes up to a marking spot 32 mm from the tipping end. Cigarettes 
are extinguished by pulling off the burning core to preserve the cigarette filter.  
 
The interventions are executed at a laboratory location, separated from patient care, 
specifically facilitated to avoid smoke exposure of researchers and department personnel. The 
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local authorised university safety-board and housing-board approved this facility in 
accordance to national and local smoking legislation. 
 
Eligibility 
Patients are selectively recruited as from October 2009 by their own respiratory consultant or 
respiratory nurse during regular scheduled clinic visits, at the pulmonary diseases department 
of the Radboud University Nijmegen Medical Centre. Eligible candidates are initially selected 
from pulmonary patient files, based on the selection criteria (table 2). We recruit patients with 
COPD (defined according to current GOLD criteria),
3
 without interfering co-morbidities, who 
are current smokers, and who are capable of fulfilling the experiment physically and 
logistically. Patients with interfering factors such as asthmatic features or other interfering 
non-COPD respiratory disorders are excluded.  
 
Table 2: Eligibility 
Inclusion criteria Exclusion criteria 
 COPD GOLD stage II-III (i.e. FEV1/FVC 
<0.70 and FEV1 30-80% of predicted value) 
 Current cigarette smoking 
 Willing to provide written informed consent 
 Willing to refrain from smoking and avoid use 
of a bronchodilator > 8 hours 
 Registered in one of the recruitment institutes 
 COPD GOLD stage I or IV 
 Active asthmatic component: present asthma 
by complaints, positive histamine 
provocation test, eosinofilia or reversibility 
≥10% of predicted 
 Unable to perform the whole experiment 
physically or due to communication 
problems 
 Recent, active and relevant non-COPD 
respiratory disorders 
GOLD: global initiative for chronic obstructive lung disease; FEV1: forced expiratory volume in the 
first second; FVC: forced volume capacity. 
 
Candidates receive written information and have at least one week to consider their 
participation. The investigator (WvD) contacts candidates by telephone to address further 
questions and to provide additional information if necessary. Participants sign an informed 
consent form. The encoded identities are only accessible by the investigator and research 
assistant. The local accredited medical review ethics committee approved our protocol: CMO 
region Arnhem-Nijmegen, CMO 2009/037. We explicitly support the quit-smoking advice 
and do not interfere if a patient has initiated an attempt to quit smoking. 
 
Blinding 
Placebo and bronchodilator administrations are double-blinded. Blinding is only known to a 
research nurse, who prepares and delivers the medication for each study participant, and does 
not have any other involvement. The placebos are not distinguishable from the 
bronchodilating drugs through appearance or administration. Pulmonary function tests after 
drug administration are not performed until the final cigarette has been smoked. We will 
unblind all study medication simultaneously after the final participant has concluded the 
experiment or individually in case of a serious adverse event. 
3.3 
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Sample size calculation 
In a cross-over design with paired samples, a number of 34 patients is sufficient to 
demonstrate a medium standardised effect size (δ = 0.5) of  pre and post mean difference 
between the two different conditions (assumptions: α = 0.05, 1-β = 0.80, two-tailed testing, c 
= 7.9): n = c/δ2 + 2.20 The medium standardised effect size is derived from an interpretation of 
Feng’s study about retention dynamics.13 We base the increase in tar retention on the 
assumption that our participants execute an average smoking pattern, that bronchodilation 
results in a 20% increase of Forced Vital Capacitiy (FVC), and that this increase results in 
20% more as well as deeper smoke inhalation.
9
 Figure 1 shows our interpretation of Feng’s 
study and reveals a subsequent estimated 5% increase in tar retention caused by 
bronchodilation. The mean standard deviation of tar retention approximates 10%, based on 
three main tar substances, and results in an effect size of 0.5 (increase/standard deviation).
13
 
 
Figure 1: 20% increase (---) of a normal inhalation volume (––) leads to a mean 5% increase in 
retention (*) of 3 main tar compounds. 
 
 
 
Outcome measures 
Primary outcome will be the evaluation for both bronchodilated conditions of changes in 
cigarette smoke retention between before and after medication administration. These 
retentions are calculated by both the inhaled tar and nicotine weights (mg) minus their 
exhaled amount, divided by the inhaled amount.
13
 
 
Secondary outcomes include smoking patterns – presented by mean inhalation as well as 
exhalation volume (ml) and time (seconds) – and respiratory function by Forced Expiratory 
Volume in the first second (FEV1) and FVC. These variables will also be analysed for their 
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correlation with smoke retention. Another secondary outcome is the short-term reaction of 
biomarkers associated with cardiovascular disease in long-term studies, i.e. C-reactive protein 
and platelet activation by fibrinogen.
21-23
 Study outcomes are presented in table 3.  
 
Table 3: Study outcomes 
Primary outcome Secondary outcomes 
Smoke retention 
 
Tar (%) 
Nicotine (%) 
Pulmonary function FEV1 reversibility (%) 
FVC reversibility (%) 
  Smoking pattern Mean inhaling time and volume (sec+ml) 
Mean exhaling time and volume (sec+ml) 
Total smoking time (min) 
Amount of puffs (n) 
  Biomarkers CRP and high sensitivity CRP (mg/l) 
Fibrinogen (mg/l) 
FEV1: forced expiratory volume in the first second; FVC: forced volume capacity; CRP: C-reactive protein. 
 
Measurements 
Pilot study. Tar and nicotine yields are related to the amount of nicotine in cigarette 
filters.
13,15
 We performed a pilot study at the Food and Consumer Product Safety Authority, 
Eindhoven, the Netherlands (FCA) to determine these relations for CM6 cigarettes, when 
artificially smoked up to 32 mm from the tipping end. A Cerulean SM450 smoking machine 
performed smoking at 6 different smoking regimes – ranging from 35 ml to 55 ml per 2-
second puffs, at 1 and 2 puffs per minute. After smoking, whole cigarette filters were 
extracted in a 20 ml isopropanol-based solution and analysed for their nicotine amounts by 
gas chromatography, according to standardised operating procedures (ISO method 10315). 
For single cigarettes, tar was captured on a paired Cambridge filter pad, which was weighed 
before and after smoking to generate a gross tar weight. Subsequently these filters were 
extracted and analysed similar to the cigarette filters for their nicotine amount – i.e. nicotine 
yield – and water amounts. Subtracting the water amount from the gross tar weight, corrected 
by addition of the water amount of blank filter pads, resulted in the net tar weight, i.e. tar 
yield (ISO method 4387). The paired values resulted in an equation to calculate inhaled 
nicotine and tar amounts by cigarette filter nicotine weights. 
 
 
Table 4: Baseline characteristics 
History Medication Pulmonary Function Pre-experiment check 
 COPD GOLD-
classification 
 Pulmonary diseases 
 Other diseases 
 Smoking 
 Pulmonary 
medication 
 Co-medication 
 FEV1 and FVC pre- and 
post bronchodilation 
 Inspiratory Vital Capacity 
 Total Lung Capacity 
 Diffusion 
 Last smoke 
 Last bronchodilator use 
 Rescue bronchodilator 
last week? 
 Exacerbation last week? 
GOLD: global initiative for chronic obstructive lung disease; FEV1: forced expiratory volume in the first 
second; FVC: forced volume capacity. 
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From our pilot study, we obtained 30 valid results of paired CM6 cigarette filters and 
Cambridge filters, by 6 different smoking regimes, and generated two equations to estimate 
the inhaled amounts of tar and nicotine for our participants: nicotine inhalation (mg) = 1.4 * 
nicotine (cigarette filter) + 0.35 (R
2
 = 0.82, p< 0.01, figure 2). Tar inhalation (mg) = 20.8 * 
nicotine (cigarette filter) + 1.06 (R
2
 = 0.74, p< 0.01). 
 
Baseline assessment. By questionnaire we attain medical history, smoking history, all 
medication use, and – prior to both sessions – recent use of cigarettes, bronchodilation and 
rescue medication. FEV1 and FVC are measured each session by a portable spirometer – 
Micro loop 36-ML3535MK8, Carefusion. A comprehensive baseline pulmonary function test 
is by spirometry: Total Lung Capacity (TLC), Diffusion and Inspiratory Vital Capacity (IVC). 
Participants wear an inductive plethysmography garment – Vivometrics Lifeshirt® – that 
measures single smoking puffs real-time and facilitates smoking pattern analyses by 
Vivologic software.
13
 We calibrate the Lifeshirt® by 10 simultaneous spirometric mean tidal 
volume measurements. We attain baseline biomarkers by venous blood samples. Table 4 
summarises all baseline characteristics. 
 
Figure 2. correlation between cigarette and Cambridge filter nicotine (Pearson’s correlation 
coefficient of 0.90) 
 
 
Experiment. Each session, participants smoke two cigarettes while we mark smoke 
inhalations manually for the Lifeshirt®. In addition, these puffs will be visually identified 
during the Lifeshirt data management. After smoking the second cigarette, we measure FEV1 
and FVC twice by handheld spirometry to determine both airflow obstruction and 
reversibility. We repeat blood sampling from the same vein twice as well. In order to establish 
inhaled tar and nicotine weights, we analyse the cigarette filters at the FCA for their nicotine 
Cigarette filter nicotine (mg) 
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contents. We establish exhaled tar and nicotine weights by analyses of Cambridge filters 
similar to the pilot study.
12,13
 These Cambridge filters capture approximately all tar. To 
diminish losses, participants wear a nose clip, are instructed to inhale all smoke, and exhale 
all smoke through a mouthpiece, which connects to two parallel 55 mm Cambridge filters. We 
use inert PTFE (Teflon) tubing, PTFE filter pad holders and metal connectors, and maintained 
temperature at 40°C to prevent smoke sedimentation and condensation and to prevent filter 
pads from blocking. We reduced the dead space to 35 ml. Filter pads are re-weighed after 
smoking, only after water evaporation has stabilised. All filters are vacuum sealed and 
preserved at room temperature. Prior to analyses at the FCA, filters are re-stabilised at 22°C at 
60% relative humidity.
13,14
 
 
Statistical analysis 
We use SPSS 16.0 to statistically analyse our results. We compare medication induced 
changes in cigarette smoke retention between the placebos and bronchodilators, by mixed 
model analyses. Baseline characteristics are studied as determinants of short-term changes in 
smoke retention and cardiovascular biomarkers by univariate analysis of variance (ANOVA). 
Pulmonary function and smoking pattern are studied for a correlation with smoke retention by 
a separate correlation analyses. Regression analyses was used for our pilot study. 
 
 
DISCUSSION 
The aim of our study is to demonstrate a fundamental effect of bronchodilation on smoke 
retention as a proof of concept for our hypothesis that suggests a hazardous interactive effect 
of bronchodilation and smoking on cardiovascular disease in COPD patients. The study 
design is directed at selecting a population in which the experiment is rather safe and where 
we expect some bronchodilator effect on the FVC: COPD Gold classification II-III. In 
addition, this group represents 70% of COPD patients. We therefore believe, selection bias is  
minimal and generalisability is reasonable.
24
  
 
The power of our study benefits from the crossover design which reduces the required sample 
size. The study effect is amplified by maximum bronchodilation in one session – by 
combining a beta-2 agonist and anticholinergic bronchodilator – and maintaining maximum 
deprivation of bronchodilation in the other session. Validity of the study is consolidated by 
the following: participants have a break of one week between the first and second 
measurement session to eliminate any carry-over effects. Sessions are scheduled at 
standardised times to decrease periodicity by cyclic daytime influences.
25
 Randomisation and 
blinding throughout the experiment is guaranteed by independent research assistants, 
undistinguishable placebos and post medication pulmonary function tests after the second 
cigarette only. The way patients for the study are recruited and all other procedures used in 
the study are conform ethical standards. Participants do not have to smoke or take medication 
differently than they are used to except for pre-experimental abstinence. We optimised 
3.3 
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exhaled tar and nicotine measurements by heating of the construction to exclude smoke 
condensation, inert materials and a small dead space to avoid sedimentation, and clear 
instructions and a nose clip to prevent smoke losses. 
 
We measure inhalation and exhalation tar and nicotine amounts by a method similar to 
methods that have been proven valid in previous studies.
12-15
 To minimise variation in inhaled 
amounts of tar and nicotine, we standardised the measurements by conditioning of the 
cigarettes, lighting them electrically, and smoking them up to 32 mm from the tipping end. In 
addition, by utilising just one cigarette brand, we are able to exclude the variation of the 
brand-specific nicotine filtration efficiency. A relatively suboptimal correlation between 
cigarette filter nicotine and inhalation amounts is likely due to the influence of different 
smoking regimes, specifically puff volume. Still, we assume our crossover-based method is 
valid since differences in smoking regimes consist merely between patients and not as much 
within patients. Furthermore, daily differences in smoke patterns are accounted for by similar 
nicotine deprivation for both conditions and retention differences between before and after 
medication both sessions.  
 
CONCLUSION 
We believe we developed a valid method to study the fundamental interaction between 
bronchodilation and cigarette smoking in COPD patients that may result in different 
pulmonary smoke retentions and parallel short-term cardiovascular effects. The pilot study on 
individual smoke yield measurements appears useful for future smoke studies. Our method 
reduces sample size and the individual burden by participation is limited. We expect that our 
study will provide crucial new insights on the safety of prescribing bronchodilators to patients 
with COPD who persist in their habit of cigarette smoking. 
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ABSTRACT 
 
Background. Bronchodilators are the cornerstone for symptomatic treatment of chronic 
obstructive pulmonary disease (COPD). Many patients use these agents while persisting in 
their habit of cigarette smoking. We hypothesized that bronchodilators increase pulmonary 
retention of cigarette smoke and hence the risk of smoking-related (cardiovascular) disease. 
Our aim was to investigate if bronchodilation causes increased pulmonary retention of 
cigarette smoke in patients with COPD. 
 
Methods. A double-blinded, placebo-controlled, randomized crossover trial, in which COPD 
patients smoked cigarettes during undilated conditions at one session and maximal 
bronchodilated conditions at the other session. Co-primary outcomes were pulmonary tar and 
nicotine retention. We performed a secondary analysis that excludes errors due to possible 
contamination. Secondary outcomes included the biomarkers C-reactive protein and 
fibrinogen, and smoke inhalation patterns. 
 
Results. Of 39 randomized patients, 35 patients completed the experiment and were included 
in the final analysis. Bronchodilation did not significantly increase tar retention (-4.5%, 
p=0.20) or nicotine retention (-2.6%, p=0.11). Secondary analysis revealed a potential 
reduction of retention due to bronchodilation: tar retention (-3.8%, p=0.13), and nicotine 
retention (-3.4%, p=0.01). Bronchodilation did not modify our secondary outcomes. 
 
Conclusions. Our results do not support the hypothesis that cigarette tar and nicotine 
retention in COPD patients is increased by bronchodilation, whereas we observed a possibility 
towards less retention. 
 
Trial registration: www.clinicaltrials.gov: NCT00981851 
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hronic obstructive pulmonary disease (COPD) is a highly prevalent chronic 
condition, characterized by debilitating and progressive airflow obstruction.
1
  Unlike 
cardiovascular disease and other chronic conditions, prevalence and mortality of 
COPD still increase globally.
1-3
 In addition, patients with COPD often suffer from co-
morbidity (cardiovascular disease; lung cancer) that contributes to mortality.
4;5
 Apart from an 
independent association between COPD and cardiovascular disease, both diseases share a 
common risk factor, i.e. cigarette smoking.
1;6;7
 Whereas approximately 90% of COPD is 
caused by smoking, about 50% of patients with diagnosed COPD continue to smoke, often 
despite intensive smoking cessation programs.
7-9
  
 
Bronchodilators are the cornerstone of the pharmacotherapeutic management of COPD 
patients, with a current trend towards the use of long-acting and ultra long-acting drugs.
1;8;10
 
However, there is a controversy about the safety of bronchodilators, which in particular 
concerns their cardiovascular effects.
11
 Recent large randomized controlled trials observed a 
possible protective effect on (cardiovascular) mortality, but meta-analyses report either no or 
a hazardous effect.
12-16
 
 
We hypothesized an interaction between bronchodilators and smoking that may explain these 
discrepancies in safety profiles.
17
 Through a change in hyperinflation and/or breathing 
patterns, bronchodilators could affect COPD patients’ smoking behavior – including both 
increased and deeper smoke inhalation. Consequently, a more efficient smoke exposure and a 
subsequent increase in smoke retention could result in a modified risk profile to develop 
cigarette smoke-related diseases like cardiovascular disease. Potentially, this interaction might 
have implications in physicians’ decision making with regard to bronchodilator treatment in 
COPD patients who persist in their habit of smoking cigarettes. 
 
Continuing our pilot study on interaction between smoking and bronchodilation
18
, the study 
reported in this paper hypothesized that maximal bronchodilation would increase the retention 
of cigarette smoke constituents, such as tar and nicotine, in COPD patients who smoke 
cigarettes, and consequently would increase biomarkers, such as C-reactive protein and 
fibrinogen. 
 
 
METHODS 
We conducted a randomized, double-blind, double-dummy, placebo-controlled, crossover 
trial in patients with COPD, in which participants smoked cigarettes during both undilated 
and maximal bronchodilated conditions. Study methods have been ethically approved by the 
CMO region Nijmegen-Arnhem (CMO 2009/037), registered at www.clinicaltrials.gov 
(NCT00981851), and published in detail.
19
 
 
 
C 
3.4 
84 
 
Participants 
COPD patients were recruited from respiratory clinics of the Radboud University Nijmegen 
Medical Centre (RUNMC), two neighboring general hospitals, and nine family practices. 
Selection criteria included: age 40 to 80 years; a diagnosis of COPD, GOLD stage 2 or 3,
1
 
current smokers; absence of interfering pulmonary diseases, including asthma. Participants 
were advised on smoking cessation. 
 
Interventions 
Participants abstained from smoking and bronchodilators according to a pre-specified 
schedule. In a designated laboratory room of the RUNMC, participants smoked one Coresta 
Monitor No. 6 (CM6) cigarette before and one after inhalation of placebo aerosols in one 
session, and before and after maximal bronchodilation in another session, with one week 
between both sessions. During the measurements, participants were instructed to smoke as 
they normally did. Smoking conditions were standardized, including wearing a nose clip, 
electrical cigarette ignition, smoking up to 32 mm from the filter end, and exhaling through 
Cambridge filters. These filters trap 99.9% of particles larger than 100 nm, also referred to as 
tar (ISO 3308).
20
 CM6 cigarettes were conditioned at 22°C and 60% relative humidity for at 
least 2 days (ISO 3308). Maximal bronchodilation was achieved by two aerosol inhalers: 5 µg 
tiotropium Respimat®, and 400 µg salbutamol via Volumatic spacer.
1
  
 
Figure 1. Time schedule of experiment, including interventions and 
measurements. 
 
 
Outcomes and measurements 
Changes of percentage of pulmonary retention of tar and nicotine were the co-primary 
outcomes. The proportional retention equals: (inhalation weight – exhalation weight) / 
inhalation weight. Inhalation weights of tar and nicotine were calculated from a regression 
model based on cigarette filter nicotine weight analysis, including corrections from 
simultaneous blank filter measurements.
19
 As participants exhaled through Cambridge filters, 
tar exhalation weights were derived from filter weight increments after smoking, and nicotine 
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exhalation weights from their substance analyses. We also evaluated cardiovascular risk 
biomarkers from blood samples, smoke inhalation patterns from the Vivometrics Lifeshirt®, 
and pulmonary function by spirometry (figure 1). Consequently, our secondary outcomes 
included: plasma C-reactive protein and fibrinogen levels; smoke in- and exhalation volume 
and time; forced expiratory volume in one second (FEV1) and forced volume capacity (FVC). 
 
Sample size and randomization 
Our statistician (RA) determined that in a cross-over design with paired samples, a number of 
34 patients is sufficient to demonstrate a pre and post mean difference of smoke retention 
between undilated and bronchodilated smoking conditions (assumptions: α = 0.05, 1-β = 0.80, 
two-tailed testing, c = 7.9): n = c/δ2 + 2.21 We calculated a medium standardized effect size 
(δ) of 0.5, derived from a 10% standard deviation of smoke retention and a 5% increase of 
smoke retention (as due to a 20% change of FVC).
19
 The medication sequence was obtained 
by computer-generated block randomization with a block size of 2. An independent research 
nurse concealed allocation and secured double-blinding by preparing identical active 
medication and placebo canisters. 
 
Statistical analyses 
Individual statistical differences between undilated and bronchodilated smoking conditions 
were analyzed by linear mixed models, including adjustments for potential learning and 
carryover effects. As suspicions were raised of filter contamination in 8 sessions (their unused 
blank filters showed positive measurements of nicotine), we performed a secondary analysis 
without these sessions to control for error by contamination. Furthermore, we analyzed the 
effect of bronchodilation on biomarkers, smoke inhalation patterns and pulmonary function. 
We evaluated associations between the level of smoke retention and the level of obstruction, 
by Pearson’s correlation analyses, to test for dose-effect relationships. All analyses were 
performed in SPSS 16.0. P-values were set at 0.05 for statistical significance testing, 
confidence intervals (CI) at 95%. 
 
Figure 2. CONSORT flow chart of patients progressing through the randomized controlled study. 
 
 
 
 
 
  
 
 
Hospital: 139 eligible patients  
Family practice: 102 eligible patients 
 
39 patients 
randomized 
15 participants in B* 
included in final analysis 
 
21 patients allocated to 
administration order A* 
4 patients lost-to-follow-up: 
-2 personal reasons 
-2 protocol non-compliance 
 
119 patients not included: 
-54 did not reply 
-46 did not fulfill criteria 
-11 no informed consent 
-5 no time 
-3 other reasons 
 
83 patients not included: 
-74 did not reply 
-8 did not fulfill criteria 
-1 no informed consent 
20 participants in A* 
included in final analysis 
18 patients allocated to 
administration order B* 
* Order A: first session active bronchodilators, second session placebos; order B: first session 
placebos, second session active bronchodilators. 
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RESULTS 
Study population 
Patients were recruited from October 2009 to March 2011. Of 241 eligible candidates 
approached, we recruited 39 patients for  participation, of whom 35 (90%) completed the 
study and were included in the final analyses (figure 2). Of 70 measurement sessions (each 
session includes one of the two measurement sessions of one patient), 14 sessions had missing 
values on nicotine exhalation due to values below the limit of quantification, and 5 sessions 
showed negative tar retentions (-3% to -11%). Eight sessions suffered from positive blanks, 
including 3 of the 5 sessions with negative tar retentions. 
 
Table 1 shows the baseline characteristics at randomization: 18 males (51%); mean (± sd) age 
59.5 years (± 8.8); mean FEV1 1.74 l (± 0.53) or 60% (± 12) from predicted; mean cumulative 
smoking exposure 37.3 packyears (± 25.7). FEV1 and FVC both increased after 
bronchodilation (FEV1 277 ml (11% from predicted), p<0.001; FVC 200 ml, p<0.001) but not 
after placebo (FEV1 -46 ml (-2% from predicted, p=0.13); FVC -50 ml, p=0.20). During 9 
measurement sessions, patients were unable to properly smoke because smoking provoked 
coughing fits or dyspnoea. These coughing fits and dyspnoea resolved after the intervention at 
4 of 5 sessions with active bronchodilation contrary to 1 of 4 sessions with placebos. 
 
Table 1. Baseline demographic and clinical characteristics of the 35 patients included in the study trial 
and analyzed, according to randomization. Dichotomous variables are presented as total number 
(percentage), continuous variables as means (±standard deviation).  
 Total 
(N=35) 
Bronchodilation 1
st
 visit 
(N=20) 
Placebo 1
st
 visit 
(N=15) 
Age (years) 59.5 (±8.8) 59.9 (±8.2) 59.0 (±9.8) 
Sex (male) 18 (51%) 9 (45%) 9 (60%) 
Packyears 37.3 (±25.7) 34.6 (±20.1) 41.0 (±32.1) 
Pulmonary function    
FEV1% (post BD) 60 (±12) 59 (±13) 62 (±12) 
Reversibility* (%) 4.2 (±4.4) 3.9 (±4.6) 4.7 (±4.1) 
FVC (post BD) 3.61 (±1.10) 3.57 (±1.26) 3.67 (±0.88) 
FEV1/FVC (post BD) 0.50 (±0.12) 0.47 (±0.12) 0.52 (±0.10) 
TLC% 106 (±16) 110 (±18) 101 (±11) 
Diffusion(DLco)% 57 (±15) 55 (±16) 59 (±13) 
Cardiovascular disease 11 (31%) 6 (30%) 5 (33%) 
Packyears: calculated by former and current smoking habit; FEV1%: forced expiratory volume in one second 
as percentage from predicted; FVC: forced vital capacity (litre); TLC%: total lung capacity as percentage from 
predicted; Diffusion(DLco)%: carbon monoxide diffusing capacity as percentage from predicted; 
Cardiovascular disease includes cardiac, cerebral en peripheral vascular disease (not hypertension); *Response 
on bronchodilator >10 minutes after administration. 
 
Effects on retention of smoke constituents 
We observed mean (± sd) pulmonary retentions of nicotine and tar of 83% (± 16) and 53% (± 
22), respectively, from smoking prior to inhalation of any medication. Mean inhalation 
weights of tar and nicotine were 18.0 mg and 1.5 mg, and did not statistically differ between 
the placebo or bronchodilators sessions (p>0.90). Linear mixed model analysis revealed that 
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bronchodilation did not increase tar retention (-4.5%, 95%CI= -11.5% to 2.5%, p=0.20) or 
nicotine retention (-2.6%, -5.8% to 0.7%, p=0.11) (tables 2 and 3, and figures 3 and 4). The 
secondary analysis that controlled for contamination revealed a potential decrease of tar and 
nicotine retentions: tar -3.8% (-8.7% to 1.2%, p=0.13), and nicotine -3.4% (-5.9 to -0.8%, 
p=0.01). 
 
 
 
Table 2. Linear mixed model analysis for changes of smoke retention due to medication, adjusted for 
learning (visit) and carryover (sequence) effects. 
 Primary analysis (35 patients, 70 sessions) 
 Effect p-value 95% CI 
Change of tar retention    
Intercept 
Bronchodilation 
Visit 
Sequence 
2.8% 
-4.5% 
0.5% 
-1.2% 
0.43 
0.20 
0.88 
0.73 
  -4.2% - 9.7% 
-11.5% - 2.5% 
  -6.5% - 7.5% 
  -8.2% - 5.8% 
Change of nicotine retention    
Intercept 
Bronchodilation 
Visit 
Sequence 
6.3% 
-2.6% 
0.0% 
-5.2% 
  0.03* 
0.11 
0.99 
0.15 
   0.6% - 11.9% 
-5.8% - 0.7% 
-3.2% - 3.3% 
-12.3% - 1.9% 
Secondary analysis (35 patients, 62 sessions) 
 Effect p-value 95% CI 
Change of tar retention    
Intercept 
Bronchodilation 
Visit 
Sequence 
-2.3% 
-3.8% 
-0.1% 
3.6% 
0.41 
0.13 
0.98 
0.26 
-8.0% - 3.4% 
-8.7% - 1.2% 
-5.0% - 4.9% 
  -2.8% - 10.1% 
Change of nicotine retention    
Intercept 
Bronchodilation 
Visit 
Sequence 
2.0% 
-3.4% 
0.6% 
-0.7% 
0.16 
  0.01* 
0.62 
0.63 
-0.8% - 4.8% 
 -5.9% - -0.8% 
-1.9% - 3.2% 
-3.8% - 2.3% 
* p-value <0.05. 
 
 
 
Table 3. Mean smoke retentions before and after medication, categorized by sequence and visit. 
 Visit 1 Visit 2 
 before medication after medication before medication after medication 
Tar retention   
Sequence A 57.2% 54.7% (BD) 56.1% 57.6% (P) 
Sequence B 48.3% 51.6% (P) 46.3% 44.5% (BD) 
Nicotine retention   
Sequence A 89.3%  88.9% (BD) 85.6% 86.7% (P) 
Sequence B 75.5% 82.3% (P) 82.5% 83.4% (BD) 
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Figure 3. Change of tar retention as modified by both bronchodilation and placebo. - - - - are 
individual changes, whereas ▬ is the mean change. 
 
 
Figure 4. Boxplots for change of tar retention (%) from smoking a 
cigarette, after administration of both bronchodilator and placebo. 
 
 
 
 
 
 
 
 
 
Effects on biomarkers and smoke inhalation patterns 
Before smoking, mean (± sd) high sensitivity-CRP was 7.65 mg/l (± 9.0) and mean (± sd) 
fibrinogen was 4,129 mg/l (± 826). Mean (± sd) inhalation and exhalation volumes and times 
were 831 ml (± 652) and 1,773 ml (± 1,025), and 1.9 seconds (± 0.78) and 5.3 seconds (± 
1.7), respectively. Mean (± sd) smoke inhalation volume-FVC ratio was 28% (± 18). Mean (± 
sd) smoking time and number of puffs were 7.1 minutes (± 1.4) and 12.7 puffs (± 2.9). We did 
not observe any statistical differences in changes of biomarkers or smoke inhalation patterns 
between the placebo aerosols and active bronchodilators sessions (table 4). 
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Table 4. The effect of bronchodilators on the secondary outcomes of biomarkers and smoke inhalation 
patterns, adjusted for both learning and carryover effects. 
 Effect p-value 95% CI 
Biomarkers    
Hs-CRP (mg/l) 0.01 0.86 -0.15 – 0.18 
Fibrinogen (mg/l) 26 0.48  -48 – 248 
Smoke inhalation pattern    
Inhalation volume (ml) 71 0.22  -81 – 173 
Exhalation volume (ml) 92 0.36 -110 – 294 
Inhalation time (sec) 0.13 0.32 -0.13 – 0.38 
Exhalation time (sec) -0.22 0.40 -0.75 – 0.31 
Smoking time (sec) 13 0.37 -16 – 41 
Number of puffs -0.21 0.55 -0.92 – 0.50 
CI: confidence interval. 
 
Correlations on smoke retention and pulmonary function 
No correlation was found between level of airflow obstruction and tar and nicotine retention. 
For both the change in FVC and change in FEV1% from predicted we observed a possible 
weak inverse correlation with change of nicotine retention: Pearson’s r = -0.25 (p= 0.07) and -
0.24, (p= 0.07), respectively, and between change in FEV1% from predicted and tar retention: 
-0.22 (p= 0.08). None of these reached statistical significance. 
 
 
DISCUSSION 
Our study did not confirm our hypothesis that bronchodilation increases the pulmonary 
retention of cigarette smoke as measured by tar and nicotine retention, nor could we confirm 
that bronchodilation affects the smoke inhalation pattern or smoking-related biomarkers. 
When excluding the sessions with suspected contaminated filters, we observed a potential 
decrease of smoke retentions. 
 
Several studies reported the effects of bronchodilators on mortality, with varying results.
12-16
 
However, these trials usually suffered from methods not primarily designed to study 
(cardiovascular) mortality and did not adjust for the possible interaction between 
bronchodilators and smoking. To the best of our knowledge, our study is the first to address 
smoke retention in COPD patients and in particular in relation to bronchodilation. The only 
studies we found to compare our findings with, looked at cigarette smoke retention in healthy 
subjects: with normal smoke inhalation patterns, mean tar retention (50-80%) and mean 
nicotine retention (90-100%) seem similar to our results.
22-27
 These figures support our 
method to measure smoke retention. Furthermore, for comparative purposes smoking 
inhalation volumes are usually measured as a proportion of the vital capacity. In healthy 
subjects, previous studies revealed a smoking inhalation volume similar to our results of 
around 25% of the vital capacity,
24;28;29
 which indicates our method for measuring smoke 
inhalation patterns is valid as well.  
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Strengths an limitations 
Apart from our original hypothesis, the crossover design, standardization, and baseline 
measurements of our outcomes are important strengths. These methods decreased variation 
and, consequently, reduced the number of patients needed for the study. Another strength is 
that patients finished participation within a month and hence our study would not have a 
significant impact on any intermediate smoking cessation attempts. Furthermore, we 
diminished cigarette variation by standardization and using conditioned CM6 cigarettes, 
known for their minimal variability. In particular, we countered the variation of between-
patient-differences in smoke inhalation and puff patterns by the crossover design. In addition, 
we minimized day-to-day variations by comparing individual smoke retentions of cigarettes 
smoked on the same morning; before and after medication. On the other hand, the 
standardized settings like exhaling through Cambridge filters may have interfered with the 
‘natural’ smoking behavior as participants seemed to exhale relatively long, whereas the nose 
clips may have also modified inhalation through affecting the patients’ sense of dyspnoea. 
 
A possible limitation of our study was the fact that smoking provoked cough and/or dyspnoea 
in a number of patients. This may have interfered with our measurements, and consequently 
with the findings on smoke retention.
22;24;25
 Problems in the measurement of tar and nicotine 
may have influenced the findings: we calculated negative tar retentions (i.e., more tar exhaled 
than the amount initially inhaled) in 5 sessions. These negative tar retentions were 
accompanied by low nicotine retentions, which suggests a possible mathematical error in the 
lower retention ranges. In addition, we observed 14 sessions with nicotine exhalation values 
below the limit of quantification, reflecting a near 100% nicotine retention suggesting 
possible underestimation of the mean nicotine retention (83%) in our study. Another 
limitation is that our sample size calculation was designed to detect a 5% change of smoke 
retention, which makes it impossible to preclude effects below this level. 
 
The positive nicotine measurements of unused filter blanks at several sessions need further 
explanation. If the nicotine was derived from cigarette smoke, the nicotine values of the 
positive blanks indicate an amount that would have been visible as a change in the filter color. 
As filters appeared blank on observation, the most likely explanation is a laboratory-based 
contamination of the filters or extract solutions with nicotine, for which no further 
clarification or source could be found. According to ISO-standards one should discard and 
recommence these measurements. However, filters could not be analyzed again since their 
contents were already fully extracted. We could not conduct these measurements again, and 
hence corrected for these positive blanks with the assumption that the contamination was 
similar for either all Cambridge filters or all cigarette filters that were analyzed in the same 
batch. In addition, we performed a secondary analysis that excluded the sessions with possible 
systematic errors due to laboratory contamination. This secondary analysis did not confirm an 
increase of smoke retention due to bronchodilation either, but instead a possible decrease. 
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Finally, our study results cannot be directly translated to all COPD patients that persist in their 
smoking habit, although our findings seem relevant for a substantial part of the COPD 
population.
7-9
 Even more, our study aim was to demonstrate any existence of interaction, not 
generalization. 
 
Interpretation 
Our results do not confirm that bronchodilators in COPD patients increase cigarette smoke 
retention, smoking-related biomarkers or smoke inhalation patterns. Hence, it would be 
unlikely that bronchodilators increase the risk to develop cigarette smoke-related 
(cardiovascular) diseases through these mechanisms. However, final smoke exposure and 
translation into smoking-related cardiovascular risk profiles depends on various factors, 
including the number of cigarettes smoked, puff patterns, smoke inhalation patterns, and 
pulmonary smoke retention, penetration and transposition. Our study aimed to demonstrate 
that bronchodilators in COPD patients who continue to smoke might modify some of these 
factors, i.e., smoke retention and smoke inhalation patterns. The effect of bronchodilators on 
the other factors remains unclear and further studies on the interactive effect in the general 
COPD population and to what extent this interaction affects final cardiovascular disease are 
needed to address this. Further studies could add to a more deliberate prescription of 
bronchodilators to COPD patients who persist in their smoking habit, in particular those who 
already suffer from cardiovascular disease. 
 
In addition, different COPD phenotypes may be affected differently by these factors of smoke 
exposure. Specifically, the possible effect of less smoke retention due to bronchodilation as 
observed in our secondary analysis, would be rather plausible in our cohort. Whilst the 
reversibility of obstruction, as measured by FEV1% and FVC, might be inversely correlated 
with smoke retention (near statistical significance), this reversibility appeared higher in 
patients that received bronchodilation, which may suggest that reduction of obstruction may 
cause an improved exhalation of hazardous smoke constituents and hence less retention. More 
specific, air turbulence in the airways of COPD patients may increase impaction and retention 
of smoke constituents. Although in the current study bronchodilators did not affect smoke 
inhalation patterns, the reduced obstruction could result in less turbulence and deposition, 
resulting in less retention. 
 
Conclusions 
Our results suggest that the use of bronchodilators in COPD patients that continue cigarette 
smoking is unlikely to increase smoke retention. Moreover, we observed a trend towards the 
opposite. As yet, there is a need to confirm our findings in an independent study sample and 
on other risk factors, and ultimately to study the effect of possible interaction on cigarette 
smoke-related (cardiovascular) diseases. 
 
 
3.4 
92 
 
REFERENCE LIST 
1. Global Strategy for the Diagnosis, 
Management and Prevention of COPD, 
Global Initiative for Chronic Obstructive 
Lung Disease (GOLD). www.goldcopd.com. 
Accessed August 2011. 
2. Jemal A, Ward E, Hao Y et al. Trends in the 
leading causes of death in the United States, 
1970-2002. JAMA 2005; 294(10):1255-1259. 
3. Lopez AD, Shibuya K, Rao C et al. Chronic 
obstructive pulmonary disease: current burden 
and future projections. Eur Respir J 2006; 
27:397-412. 
4. Chatila WM, Thomashow BM, Minai OA et 
al. Comorbidities in chronic obstructive 
pulmonary disease. Proc Am Thorac Soc 
2008; 5(4):549-555. 
5. Curkendall SM, DeLuise C, Jones JK et al. 
Cardiovascular disease in patients with 
chronic obstructive pulmonary disease, 
Saskatchewan Canada cardiovascular disease 
in COPD patients. Ann Epidemiol 2006; 
16(1):63-70. 
6. Teo K.K., Ounpuu S., Hawken S. et al. 
Tobacco use and risk of myocardial infarction 
in 52 countries in the INTERHEART study: a 
case-control study. Lancet 2006; 
368(9536):647-658. 
7. Doll R, Peto R, Boreham J et al. Mortality in 
relation to smoking: 50 years' observations on 
male British doctors. BMJ 2004; 
328(7455):1519. 
8. Schermer T, Heijdra Y, Zadel S et al. Flow 
and volume responses after routine salbutamol 
reversibility testing in mild to very severe 
COPD. Respir Med 2007; 101(6):1355-1362. 
9. Ellerbeck EF, Mahnken JD, Cupertino AP et 
al. Effect of varying levels of disease 
management on smoking cessation: a 
randomized trial. Ann Intern Med 2009; 
150(7):437-446. 
10. Cazzola M, Matera MG. Novel long-acting 
bronchodilators for COPD and asthma. Br J 
Pharmacol 2008; 155(3):291-299. 
11. Anthonisen NR, Connett JE, Enright PL et al. 
Hospitalizations and mortality in the Lung 
Health Study. Am J Respir Crit Care Med 
2002; 166(3):333-339. 
12. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ 
et al. Tiotropium and risk for fatal and 
nonfatal cardiovascular events in patients with 
chronic obstructive pulmonary disease: 
Systematic review with meta-analysis. Respir 
Med 2009; 103(10):1421-1429 
13. Celli B, Decramer M, Kesten S et al. 
Mortality in the 4-year trial of tiotropium 
(UPLIFT) in patients with chronic obstructive 
pulmonary disease. Am J Respir Crit Care 
Med 2009; 180(10):948-955. 
14. Salpeter SR, Ormiston TM, Salpeter EE. 
Cardiovascular effects of beta-agonists in 
patients with asthma and COPD: a meta-
analysis. Chest 2004; 125(6):2309-2321. 
15. Calverley PM, Anderson JA, Celli B et al. 
Salmeterol and fluticasone propionate and 
survival in chronic obstructive pulmonary 
disease. N Engl J Med 2007; 356(8):775-789. 
16. Singh S, Loke YK, Enright PL et al. Mortality 
associated with tiotropium mist inhaler in 
patients with chronic obstructive pulmonary 
disease: systematic review and meta-analysis 
of randomised controlled trials. BMJ 2011; 
342:d3215 
17. van Dijk WD, Heijdra Y, Scheepers PT et al. 
Interaction in COPD experiment (ICE): A 
hazardous combination of cigarette smoking 
and bronchodilation in chronic obstructive 
pulmonary disease. Med Hypotheses 2010; 
74(2):277-280. 
18. van Dijk WD, Lenders JW, Holtman J et al. 
Bronchodilation and Smoking Interaction in 
COPD: A Cohort Pilot Study to Assess 
Cardiovascular Risk. Respiration 2011. doi: 
10.1159/000326921. Epub ahead of print. 
19. van Dijk W, Scheepers P, Cremers R et al. A 
method to study the effect of bronchodilators 
on smoke retention in COPD patients: study 
protocol for a randomized controlled trial. 
Trials 2011; 12(1):37. 
20. Pryor WA, Stone K, Zang LY et al. 
Fractionation of aqueous cigarette tar extracts: 
fractions that contain the tar radical cause 
DNA damage. Chem Res Toxicol 1998; 
11(5):441-448. 
21. Chan YH. Randomised controlled trials 
(RCTs)--sample size: the magic number? 
Singapore Med J 2003; 44(4):172-174. 
22. Feng S, Plunkett SE, Lam K et al. A new 
method for estimating the retention of selected 
smoke constituents in the respiratory tract of 
smokers during cigarette smoking. Inhal 
Toxicol 2007; 19(2):169-179. 
23. McGrath C., Warren N, Biggs P et al. Real-
time measurement of inhaled and exhaled 
93 
 
cigarette smoke: Implications for dose. 
Journal of Physics 2009; Conference Series 
151:012018. 
24. Dickens C, McGrath C, Warren N et al. 
Puffing and inhalation behaviour in cigarette 
smoking: implications for particle diameter 
and dose. Journal of Physics 2009; 
Conference series 151:012019. 
25. Armitage AK, Dixon M, Frost BE et al. The 
Effect of Inhalation Volume and Breath-Hold 
Duration on the Retention of Nicotine and 
Solanesol in the Human Respiratory Tract and 
on Subsequent Plasma Nicotine 
Concentrations During Cigarette Smoking. 
Contributions to Tobacco Research 2004; 
21(4):240-249. 
26. Armitage AK, Dixon M, Frost BE et al. The 
effect of tobacco blend additives on the 
retention of nicotine and solanesol in the 
human respiratory tract and on subsequent 
plasma nicotine concentrations during 
cigarette smoking. Chem Res Toxicol 2004; 
17(4):537-544. 
27. Baker RR, Dixon M. The Retention of 
Tobacco Smoke Constituents in the Human 
Respiratory Tract. Inhal Toxicol 2006; 
18(4):255-294. 
28. Nil R, Buzzi R, Battig K. Effects of different 
cigarette smoke yields on puffing and 
inhalation: is the measurement of inhalation 
volumes relevant for smoke absorption? 
Pharmacol Biochem Behav 1986; 24(3):587-
595. 
29. Zacny JP, Stitzer ML, Brown FJ et al. Human 
cigarette smoking: effects of puff and 
inhalation parameters on smoke exposure. J 
Pharmacol Exp Ther 1987; 240(2):554-564. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
 
 
 
 
 
 
 
Chapter 3.5 
Short-acting anticholinergic bronchodilation 
does not increase cardiovascular events in 
smokers with mild to moderate pulmonary 
obstruction. 
 
Emmy de Jong 
Wouter van Dijk 
Yvonne Heijdra 
Jacques Lenders 
Chris van Weel 
Reinier Akkermans 
Tjard Schermer 
 
 
 
Respirology. 2012 Dec 26. doi: 10.1111/resp.12040 
 
3.5 
96 
 
ABSTRACT 
 
Background and objective.  Or: We hypothesized that bronchodilation in patients with 
chronic obstructive pulmonary disease (COPD) increases the smoke-related risk to develop 
cardiovascular disease. In this paper, we studied  the effect of short-acting anticholinergic 
bronchodilation and smoking on cardiovascular events. 
 
Methods. We performed a secondary analysis on data from the Lung Health Study, a large 
randomized clinical trial of smokers with mild to moderate pulmonary obstruction, 35 to 60 
years old, without cardiovascular co-morbidity. We used Cox proportional survival analysis, 
controlling for several confounders, to study the effect on 5-year risk of fatal and/or nonfatal 
cardiovascular events.  Secondary outcome encompassed fatal and nonfatal coronary events. 
 
Results. Of 2,745 participants, 23 (0.8%) died of cardiovascular disease. One hundred and 
sixty two participants were hospitalized for a cardiovascular event, and 94 participants due to 
a coronary event. Survival analysis revealed no effect between smoking and short-acting 
anticholinergic bronchodilation on fatal and/or nonfatal cardiovascular events, HR=1.12 
(0.58-2.19), nor on coronary events: HR=1.46 (0.60-3.56). 
 
Conclusion. Our study results show that short-acting anticholinergic bronchodilation had  no 
detrimental effect on cardiovascular disease, in smokers with mild to moderate pulmonary 
obstruction. 
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hronic obstructive pulmonary disease (COPD) is one of the most prevalent chronic 
disease worldwide and is characterized by progressive not fully reversible airway 
obstruction.
1-3
 A substantial proportion of COPD-related mortality and morbidity is 
due to cardiovascular disease.
4,5
 The key symptomatic treatment in COPD is based on inhaled 
bronchodilators.
1
 Whether or not the use of bronchodilators is associated with cardiovascular 
morbidity and mortality is still a matter of debate.
6-10
 
 
COPD and cardiovascular diseases share smoking as the same risk factor. 
11,12
 Smoking 
cessation is the most important treatment to improve prognosis in patients with COPD,
12-14
 
and to reduce their risk of death from cardiovascular disease.
15
 However, about 50% of all 
patients with COPD continue smoking,
12,16,17
 whilst most of them use bronchodilators to 
reduce their respiratory symptoms.
1,17,18
 
 
Previous studies have investigated the health risks of smoking or the safety of bronchodilation 
in patients with COPD. We have recently hypothesized an interaction between the risk factor 
of smoking and the treatment with bronchodilation in bronchodilator safety profiles in 
COPD.
19
 We hypothesized that bronchodilation affects patients’ cigarette smoking through 
reducing pulmonary hyperinflation, increase smoke inhalation, and it could increase the 
harmful effects of smoking, including cardiovascular disease. If correct, this would have 
major consequences for the pharmacological management of COPD patients who continue to 
smoke. 
 
Our aim for the current study was to investigate the risk of developing cardiovascular disease 
secondary to smoking, bronchodilation and their interaction. Such a study requires a large 
representative sample of subjects with COPD, with valid longitudinal documentation on their 
smoking status, bronchodilator use, and incidence of cardiovascular events. The Lung Health 
Study (LHS) database largely fulfils these criteria.
20
  
 
 
METHODS 
We performed a secondary analysis on the data from the LHS research materials, as obtained 
from the National Heart, Lung and Blood Institute data repository information coordinating 
center. The LHS is a large multicenter randomized placebo-controlled clinical trial in adult 
smokers, with a 5-year follow-up period. The LHS studied the effect of intensive smoking 
cessation intervention and short-acting inhaled anticholinergic bronchodilator therapy with 
ipratropium on pulmonary function decline, overall morbidity and mortality in subjects with 
mild obstructive pulmonary disease.
15,20
 Their  study protocol and consent forms were 
approved by the institutional review boards of each of the 10 cooperating clinical centers as 
well as the Data Coordinating Center before initiation of the original study.
21
 
 
 
C 
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Study subjects and interventions 
The LHS recruited 5,887 smokers from the general population in North America between 
November 1986 and January 1988. At baseline, participants were 35 to 60 years old, were 
current smokers, and were at high risk for COPD as defined by a post-bronchodilator forced 
expiratory volume in 1 second (FEV1) over vital capacity ratio <0.70 and FEV1 between 55% 
and 90% of the predicted value. Those with serious illness such as myocardial infarction or 
stroke within the past 2 years, other important conditions including hypertension, those on 
medications like beta-blockers and insulin, and those who already used bronchodilators were 
excluded. Participants that gave written informed consent were randomized to smoking 
cessation intervention or usual care and bronchodilator  with ipratropium bromide aerosol 
inhaler, 40 µg, three times a day, or matching placebo treatment. A detailed description of the 
original LHS study protocol has been published elsewhere.
20,21
 For the current analysis, we 
selected LHS participants who continued smoking throughout the study period as smokers, 
and included non-smokers as those participants who were consistently abstinent ever since 
their first annual visit. We excluded recurrent smokers from our analysis. We considered 
participants who had been allocated to the ipratropium group as ‘bronchodilator users’, and 
participants from the placebo group as ‘non-bronchodilator users’. Participants from the usual 
care group were excluded as they did not receive any smoke intervention and were not 
blinded for bronchodilator therapy. We excluded participants that did not have any follow-up 
data. 
 
Measurements and outcomes 
Participants were invited for annual visits to one of the 10 involved study centers. The visits 
included spirometry, health questionnaires, trial medication use, and self-reported  smoking. 
We included only participants whose smoking status was validated by exhaled carbon 
monoxide measurements. Participants were asked about hospitalizations during the study 
period, which were validated by consulting hospital records, emergency room records,  and 
reports from eyewitnesses. Mortality and autopsy reports were collated. Morbidity and 
mortality were reported by days from randomization to an event.   Besides non-cardiovascular 
causes, the original LHS investigators categorized mortality into several cardiovascular 
causes, i.e. coronary heart disease (CHD) and cardiovascular disease (not CHD). Causes of 
cardiovascular hospitalization included coronary heart disease, cardiovascular disease (not 
CHD), congestive heart failure and stroke. 
 
Our primary outcome was the composite outcome of any cardiovascular hospitalizations and 
any cardiovascular mortality. It included the time to event as determined by the number of 
days from randomization to the cardiovascular event. The composite of fatal and nonfatal 
coronary events was also analyzed separately. We did not analyze fatal events separately due 
to the small number of events for interaction analysis. 
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Statistical analysis 
We used Cox proportional hazards regression models. First, we performed a backward 
multiple regression analysis of short-acting anticholinergic bronchodilation and smoking 
status together with all possible confounders to construct our survival model, including: sex, 
age, FEV1 as percentage of the predicted value, mean arterial blood pressure (1/3 systolic 
blood pressure + 2/3 diastolic pressure), body mass index, diabetes, alcoholic drinks per week 
and level of dyspnoea as defined by Medical Research Council dyspnoea scale. Covariates 
with a p-value >0.10 were dropped from the model. Finally, we added bronchodilation and 
smoking status if not already included in the final model, together with their interaction term. 
Statistically significant associations in the final model were defined as <0.05. 
 
 
Figure 1. Flow chart of LHS participant selection and grouping. 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Exclusion of intermittent smokers, participants without follow-up and participants from the 
usual care group, resulted in a total of 2,745 individuals for our analysis (figure 1). Table 1 
describes the baseline characteristics according to the study group as based on smoking status 
and short-acting anticholinergic bronchodilation. Table 2 shows information of cardiovascular 
events by study group during the five year follow-up. One hundred and eighty one (6.6%) 
participants were affected by first fatal and/or nonfatal cardiovascular events, including 162 
(5.9 %) that met the criteria for first cardiovascular hospitalization. Ninety four (3.4%) 
participants were admitted for a coronary event. Of 81 (3.0%) participants who died during 
follow-up, 23 (0.8%) participants died due to cardiovascular disease, including 15 (0.5%) due 
to coronary heart disease.  
 
3.5 
Participants LHS 
N=5,887 
Participants selected 
N=2,745 
Current smoker 
Bronchodilation 
N=940 
Current smoker 
No bronchodilation 
N=950 
Ex-smoker 
Bronchodilation 
N=416 
Ex-smoker 
No bronchodilation 
N=439 
Excluded: 
- 47 no follow-up 
- 1,607 intermittent smokers 
Excluded: 
- 1486 usual care 
- 2 no baseline spirometry 
Participants selected 
N=4,233 
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Table 1. Baseline characteristics. Continuous values are presented as means with (SD) and binomial 
values as total numbers with (%). The groups are based on smoking status and use of the study 
bronchodilator. P-values reveal any significant differences between these groups (ANOVA). 
 No smoking Smoking p-value 
 no bronchodilation 
N = 439 
bronchodilation 
N = 416 
no bronchodilation 
N = 950 
bronchodilation 
N = 940 
 
Age (years) 49.2 (6.7) 49.0 (6.5) 48.3 (6.8) 48.2 (7.1) 0.02* 
Sex (males) 298 (68%) 264 (63%) 615 (65%) 569 (61%) 0.05 
Packyears 40 (19) 40 (19) 41 (19) 40 (19) 0.89 
BMI 26 (4) 26 (4) 26 (4) 25 (4) 0.03* 
Blood pressure (mmHg)
# 
   92 (9.5) 92 (10) 91 (10) 91 (10) 0.03* 
Alcohol (drinks/week) 4.5 (5.5) 4.2 (5.7) 4.5 (5.8) 4.3 (5.4) 0.73 
Post-BD FEV1 (% predicted) 79 (9) 78 (9) 78 (9) 78 (9) 0.03* 
Reversibility (%predicted) 3.2 (3.6) 3.3 (3.7) 3.1 (3.6) 3.0 (3.6) 0.59 
Disease severity (GOLD) 1.5 (0.5) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 0.11 
Dyspnoea (0-4)           0.5 (0.8) 0.5 (0.8) 0.7 (0.9) 0.6 (0.9) <0.01* 
* p <0.05; 
#
 Mean arterial blood pressure: (SBP + 2*DBP)/3. Two missing values were computed by overall 
means.; BD is bronchodilator. 
 
Table 2. Fatal events and hospitalizations due to cardiovascular and coronary disease. 
 No smoking 
No bronchodilation 
(N = 439) 
No smoking 
Bronchodilation 
(N = 416) 
Smoking 
No bronchodilation 
(N = 950) 
Smoking 
Bronchodilation 
(N = 940) 
Death due to CVD (%) 
   days to death (SD) 
2 (0.5%) 
1091 (943) 
3 (0.7%) 
1156 (701) 
5 (0.5%) 
1312 (363) 
13 (1.4%) 
1118 (517) 
Death due to CHD 
   days to death (SD) 
2 (0.5%) 
1091 (943) 
1 (0.2%) 
349 (-) 
3 (0.3%) 
1565 (97) 
9 (1.0%) 
1201 (466) 
1
st
 hospitalization due to CVD (%) 
   days to hospitalization (SD) 
21 (4.8%) 
1068 (471) 
21 (5.0%) 
726 (526) 
57 6.0%) 
898 (494) 
63 (6.7%) 
823 (525) 
1
st
 hospitalization due to CHD (%) 
   days to hospitalization (SD) 
12 (2.7%) 
973 (436) 
11 (2.6%) 
513 (435) 
34 (3.6%) 
941 (529) 
37 (3.9%) 
840 (500) 
CVD: any cardiovascular disease. CHD: coronary heart disease 
 
Cardiovascular events 
Multiple Cox regression analyses revealed smoking, age, sex, blood pressure, post-
bronchodilator FEV1 as percentage of predicted, and alcohol as potential confounders for first 
fatal and/or nonfatal cardiovascular events (table 3). The final analysis (table 4) did not reveal 
an interactive effect between smoking and short-acting anticholinergic bronchodilation on the 
risk of cardiovascular events: hazard ratio (HR) = 1.12 (p = 0.73, 95%CI = 0.58-2.19) 
 
Coronary events 
Multiple Cox regression analysis for the participants with a first fatal and/or nonfatal coronary 
event revealed smoking, age, sex, blood pressure, post-bronchodilator FEV1 as percentage of 
predicted, and alcohol as potential confounders (table 3). The final model (table 4) did not 
show an interactive effect between smoking and short-acting bronchodilation on the risk of 
coronary events: HR = 1.46 (p = 0.41, 95%CI = 0.60-3.56).  
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Table 3. Cox survival analysis by backward regression modeling for factors of fatal and/or nonfatal 
cardiovascular and coronary events for 2,745 patients. 
 Cardiovascular events Coronary events 
 HR p-value 95% CI HR p-value 95% CI 
Smoking 1.41   0.04 1.01-1.97 1.48   0.09 0.95-2.30 
Age (year) 1.07 <0.01 1.04-1.09 1.05 <0.01 1.02-1.09 
Sex (male) 0.43 <0.01 0.30-0.63 0.17 <0.01 0.09-0.34 
Mean blood pressure 1.02 <0.01 1.01-1.04 1.03 <0.01 1.01-1.05 
FEV1% of predicted 0.99   0.07 0.97-1.00 0.97   0.01 0.95-0.99 
Alcohol (drink/week) 0.93 <0.01 0.89-0.96 0.93 <0.01 0.89-0.97 
HR is hazard ratio; CI is confidence interval. 
 
Table 4. Cox survival analysis of fatal and/or nonfatal cardiovascular and coronary events for 2,745 
patients. All variables were included together in the final model. 
 Cardiovascular events Coronary events 
 HR p-value 95% CI HR p-value 95% CI 
Smoking 1.33   0.25 0.82-2.15 1.22   0.53 0.66-2.27 
Bronchodilation 1.13   0.67 0.64-2.01 0.90   0.78 0.41-1.94 
Interaction* 1.12   0.73 0.58-2.19 1.46   0.41 0.60-3.56 
Age (year) 1.07 <0.01 1.04-1.09 1.05 <0.01 1.02-1.09 
Sex (male)  2.33 <0.01 1.61-3.38 5.96 <0.01 2.99-11.86 
Mean blood pressure 1.02 <0.01 1.01-1.04 1.03 <0.01 1.01-1.06 
FEV1% of predicted 0.99   0.07 0.97-1.00 0.97   0.01 0.95-0.99 
Alcohol (drink/week) 0.93 <0.01 0.90-0.96 0.93 <0.01 0.89-0.97 
* Interaction between smoking and bronchodilation; HR is hazard ratio; CI is confidence interval. 
 
 
DISCUSSION 
In the current study we investigated the risk of developing cardiovascular disease due to an 
interaction between bronchodilator use and cigarette smoking. Our secondary analysis of the 
Lung Health Study data did not confirm that short-acting anticholinergic bronchodilation 
increased the smoke-related risk of fatal and/or nonfatal cardiovascular events. 
 
The major strength of this study was the  reliable and valid database of approximately 6,000 
smokers collected over the 5 year follow-up of the LHS. Although we only studied patients 35 
to 60 years old, this particular age group is prone to have cardiovascular disease due to 
smoking compared to older subjects.
11
 This population would be suitable for confirming an 
interaction between smoking and bronchodilation. The rather healthy population would have 
limited any major interference of confounders like diabetes, hypertension and cardiovascular 
disease-related medication. Other important confounders like sex and blood pressure were 
systematically measured, which allowed for statistical adjustments. As this large study was 
initiated during the 1980’s when the effectiveness of bronchodilators in COPD had not yet 
been established, subjects who used any non-study bronchodilator were excluded from study 
participation. Nowadays this would be considered unethical and it would be impossible to 
3.5 
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study a ‘non-bronchodilator’ group. Furthermore, a previous report from the LHS data is one 
of the few studies that revealed the possible hazardous effect of short-acting anticholinergic 
bronchodilators on cardiovascular disease, which may have increased the power of our study 
to reveal its hypothesized interaction with smoking.
15
 Other strengths include the participant 
selection from the general population, the prospective design, the post-bronchodilator 
spirometry testing according to ATS standards, the completeness of follow-up data, and the 
repetitive confirmation of our main study variables (i.e. smoking status, bronchodilator use 
and cardiovascular outcome) from different information sources.  
 
This study also has some weaknesses. First, although our study population comprised 2,745 
participants, the incidence of first cardiovascular events was low (1.3%). Second, as we did 
not have access to the confirmation of inhaler compliance, we had to perform an intention-to-
treat analysis, based on the randomization of bronchodilator treatment at baseline. This could 
underestimate the effect of smoking and short-acting anticholinergic bronchodilation on 
cardiovascular disease . In addition, the effect of bronchodilation in the participants of this 
study may be inferior to the current used long-acting combination therapy with adrenergic 
bronchodilators. Third, participants were all smokers at baseline. Those who were classified 
as sustained quitters had stopped smoking only 4 to 5 years ago, which may have caused an 
underestimation of the long-term effect of smoking on cardiovascular disease and its 
interaction with short-acting anticholinergic bronchodilation. Fourth, COPD is defined as the 
presence of chronic respiratory symptoms and a post-bronchodilator FEV1/FVC ratio <0.70.
1
 
Selection of participants from the LHS was not based on symptoms but on spirometric 
properties and being a current smoker only. However, as the fixed FEV1/FVC ratio is rather 
specific in young patients, and the FEV1 inclusion criterion was below 90% of predicted, we 
believe that overdiagnosis in these relatively young participants was limited.
22
  
 
Despite the present limitations of this study, we believe generalization to a large COPD 
population is reasonable, because of our large study population. In retrospect, all but one 
participants could be classified as COPD GOLD stage I or II (one participant with stage III). 
The current results cannot be generalized to patients with more severe COPD.  
 
Interpretation 
Our study did not confirm our hypothesis that the combination of smoking and short-acting 
anticholinergic bronchodilators use increase cardiovascular events. A pilot study and a 
randomized controlled trial that explored this hypothesis could not confirm an interactive 
effect on cardiovascular disease either.
23,24
 From the currently available data it appears that in 
patients with COPD who continue to smoke no different bronchodilator treatment regimen is 
required than in patients who have quitted smoking. However, the data neither exclude an 
interactive effect of smoking and short-acting anticholinergic bronchodilation on other 
smoking-related outcomes like COPD progression and/or lung cancer, nor do they exclude an 
effect on cardiovascular disease on the longer term, or in those with cardiovascular co-
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morbidity. Furthermore, the LHS participants were all smokers at baseline and even those 
who were classified as sustained quitters had stopped smoking for 4 to 5 years only. Although 
cardiovascular risk decreases rapidly after smoking cessation, recent studies show that 
mortality risk is comparable to that in never smokers only after 10 to 15 years of cessation.
25-
27
 Altogether, our study may have been underpowered for this particular purpose. Moreover, 
our study only shows a significant relation between smoking and cardiovascular events, not 
between smoking and coronary events. Smoking still needs to be discouraged though. 
 
In conclusion, we could not confirm our hypothesis that short-acting anticholinergic 
bronchodilation amplifies the effects of smoking on the 5-year cardiovascular disease in 
patients age 35 – 60 years old with mild to moderate COPD without cardiovascular co-
morbidity. 
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OPD is a highly prevalent and disabling disease, with bronchodilators being used 
frequently to treat patients’ symptoms and improve their wellbeing.1-3 Their effect on 
cardiovascular disease and mortality has been debatable though. Moreover, the 
results on safety profiles in large studies and the related meta-analyses appeared to be 
contradictory.
4-9
 Whereas the (cardiovascular) safety of bronchodilators in COPD patients has 
been under discussion throughout the years, so has its recommendation to prescribe these 
drugs in the large population of COPD patients.
10-14
  
 
To solve the deadlock of this important problem, we hypothesized an interaction between 
smoking and bronchodilation that may have caused the discrepancies across the different 
studies.
15
 We initiated studies on cigarette smoke dynamics that improved our understandings 
of smoke dynamics, optimized our experiments and interpretations, and minimized variability. 
In order to study the influence of bronchodilators on the hazardous effect of smoking, we 
performed several studies that ranged from basic mechanisms of smoke retention due to 
bronchodilators, to secondary analyses of cohort studies addressing the impact of the use of 
this medication on long-term cardiovascular outcome.  
 
Our study groups were rather heterogenic and included a wide range of patients with mild to 
severe COPD, with a wide range of post-bronchodilator reversibility. Our study on smoke 
retention enclosed a sufficient number of patients with cardiovascular disease, whereas our 
cohort studies excluded most patients with cardiovascular disease. Altogether, in these 
populations, we did not demonstrate an interaction between bronchodilators and smoking that 
increased the hazardous effects of smoking. As patients with COPD often persist in smoking 
cigarettes and most of them use bronchodilators frequently, our findings are relevant to a 
substantial part of the large COPD population, including the large group treated in primary 
care. 
 
 
CIGARETTE SMOKE AND MEASUREMENT OF PULMONARY RETENTION 
 
In general, studies on cigarette smoke toxicity and (cardiovascular) disease are complex. It is 
difficult to measure individual exposure of cigarette smoke compounds and translate this 
exposure into individual risks to develop certain diseases. To begin with, cigarette smoke 
contains numerous compounds that contribute to the final smoke exposure.
16,17
 Apart from 
continuous dynamics of cigarette smoke, exposure depends on many factors, including 
cigarette properties, puff patterns, smoke inhalation patterns and number of cigarettes 
smoked.
17-21
 Furthermore, attributive disease risks of specific compounds are unclear and 
correlations among different compounds in the complex mixture of tobacco smoke are 
various.
17,22-24
 All off the above comments apply to measurements of specific cigarette 
compounds and hence do only partly reflect final smoke exposure. In addition, disease risk 
C 
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not only depends on exposure, but also on subsequent retention and transposition of specific 
compounds. Therefore, it is even more difficult to accurately predict disease risk. 
 
In our studies on cigarette smoke, we confirmed that properties of cigarette smoke, as 
measured by size-resolved particle distributions, are highly dynamic; mostly due to ageing, 
smoking patterns, and cigarette properties, filter ventilation (blocking) in particular. In 
chapter 2.1, we reported on the existence of nanoparticles in fresh and undiluted cigarette 
smoke. Although these nanoparticles have toxic properties of unknown potency, their 
proportion appears to be smaller than 5% of the total number of particles. Furthermore, these 
nanoparticles would grow rapidly due to agglomeration. In chapter 2.2, we revealed that tar 
yields as labeled on cigarette packs poorly reflect size-resolved particle distributions, which 
confirms it poorly reflects individual cigarette smoke exposure and subsequent health 
outcomes. The poor relation is clarified by the relative small contribution of the smaller 
particles to the overall tar mass. The restrictions of these type of tar measurements for relative 
toxicity by mass values in the comparison between different cigarette types, is demonstrated 
by the poor reflection of the abundance of the smallest particles in ultralow-tar cigarettes: the 
relation between tar mass yields and the number of smaller particles would hence be poor. 
However, the study also showed that in measurements of smoke exposure and smoke 
retention, it is important to standardize cigarette conditions and smoke patterns in order to 
minimize variability in smoke yields. Although final translation of smoke exposure and 
smoke retention into disease risk is incomplete, it would be feasible to study interventions that 
affect these measures of smoke toxicity. 
 
In chapter 3.3 we desribed such a design to facilitate the study of the effect of bronchodilation 
on pulmonary smoke retention, as measured by tar and nicotine retention. Although smoke 
retention would not be a perfect surrogate measure for smoke toxicity and subsequent disease 
risk, it may adequately indicate how bronchodilation affects smoke-related disease risk. The 
design was based on minimizing variation by standardization of cigarette conditions, general 
smoking conditions and measurements of cigarette smoke by tar values, whereas the variation 
due to individual smoking conditions was countered by the crossover design. Our 
measurement of smoke retention by mass values may have slightly underestimated the 
inhalation of smoke, as the dispersed nanoparticles of fresh and undiluted cigarette smoke are 
not fully accounted for by our method. Still, this systematic error would not significantly 
affect any retention differences due to bronchodilation in our crossover design. Altogether, 
our method to measure natural cigarette smoke retentions in patients with COPD appeared 
reliable for demonstrating an effect by bronchodilation on these retentions, and subsequently 
on the risk to develop cardiovascular disease. 
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INTERACTION BETWEEN SMOKING AND BRONCHODILATION 
 
From the results of our studies on interaction, it appears that COPD patients who smoke 
cigarettes can safely use bronchodilators. Although the pilot study revealed a possible trend 
towards hazardous interaction in chapter 3.2, the trend in interaction would only decrease the 
significant beneficial effect of bronchodilators, instead of increasing the cardiovascular risk 
due to smoking. Furthermore, the main methodological issue of this pilot study was the 
initiation of the use of cardiovascular medication as surrogate markers for cardiovascular 
disease, which is less reliable than the direct measurement of cardiovascular disease.  
 
Moreover, the experimental study on smoke retention and the cohort study on cardiovascular 
outcome in chapter 3.4 and 3.5, respectively, did neither reveal a hazardous interaction. In 
chapter 3.4, we reported that bronchodilation tended to decrease smoke retention instead of 
increase, hence making it unlikely to increase the risk of cardiovascular disease through that 
mechanism. The trial was strengthened in particular by the crossover design and 
standardization of cigarettes, which minimized the variability of smoking patterns and 
cigarette conditions. Indeed, the retention of both nicotine and tar seemed reproducible, with 
individual variance of nicotine and tar retention being only 5 and 9 percent, respectively. 
Furthermore, while participants were allowed to smoke as they would normally do, the smoke 
retentions in our trial appeared to be in the same range as those from previously reported 
studies.
25-28
 The main limitation for measuring smoke retention as a surrogate for smoke 
exposure and cardiovascular disease risk is that interaction may also affect the risk through 
several other mechanisms like transposition of smoke particles, puff patterns and the number 
of cigarettes smoked. However, the smoking-related biomarkers fibrinogen and high-
sensitivity C-reactive protein, as modified by cigarette smoke exposure, did neither increase 
by the effect of bronchodilation. 
 
In addition, the secondary analysis of the large longitudinal cohort study in chapter 3.5 did 
not reveal any interaction on cardiovascular events either. This cohort enclosed a large COPD 
population and reliable data on all important variables, required to measure the effect of 
interaction on cardiovascular disease. A limitation of this study was the relative small 
incidence of cardiovascular events due to the relatively young population with only mild to 
moderate COPD, combined with a short period after smoking cessation. Hence, although the 
number of events was sufficient for analysis, the overall power of this study was somewhat 
limited.  
 
 
INTERPRETATION 
 
Although methodological issues may have interfered, the use of bronchodilators appears safe 
in COPD patients who continue smoking. We did neither confirm an interaction between 
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bronchodilators and smoking in our group of COPD patients, nor did we find an explanation 
for disparities across different bronchodilator studies on safety profiles. Our findings are 
mostly based on relatively healthy COPD patients, without a clear asthmatic component. 
Translation of our results to all COPD patients who persist in their smoking habit requires 
some further detail, including the potential exceptions of specific subgroups. Moreover, 
several factors may have caused bias and may similarly also have caused the discrepancies 
across different studies on bronchodilators and (cardiovascular) mortality.  
 
First of all, important and strong predictors of cardiovascular disease and mortality that may 
interfere with the effect of the study drug include age, sex, COPD severity as measured by 
FEV1 as percentage from predicted, reversibility, dyspnoea, and cardiovascular disease 
itself.
29
 Although our cohorts represented a wide range of COPD patients, on average patients 
were relatively young, healthy and with minor dyspnoea. In particular, cardiovascular disease 
tends to be underrepresented in our cohort studies. Likewise, the large trials and meta-
analyses on bronchodilator safety profiles excluded most patients with cardiovascular disease, 
and baseline cardiovascular risk factors were not always accounted for. However, one post-
hoc analysis of a large study on long-acting adrenergic bronchodilators did not reveal an 
interaction between baseline cardiovascular events and safety of bronchodilator treatment.
30
 
In addition, the subgroup of COPD patients who exhibits asthmatic features is of main interest 
as well, as this group tends to be excluded from most trials on bronchodilator safety profiles. 
Its proportion amongst the total COPD population is unclear, and translation of results to this 
subgroup is debatable. In particular, as bronchodilators appeared hazardous in asthmatics 
when prescribed for the long-term and without inhaled corticosteroids. 
 
Apart from COPD patients with cardiovascular disease and/or asthma, (other) COPD 
phenotypes might influence interaction between bronchodilator use and smoking as well. 
Indeed, our trial revealed a subgroup of patients who had difficulty smoking without 
sufficient bronchodilation. These patients would be disadvantaged by bronchodilation due to 
its facilitation of smoking. Otherwise, COPD patients with a phenotype that allows improved 
exhalation of cigarette smoke due to bronchodilation would likely benefit. Although 
phenotyping has been previously proposed to characterize the COPD heterogeneity, 
classification is currently incomplete.
31
 
 
Secondly, based on good clinical practice, bronchodilators have to be available and accessible 
in current follow-up trials, at least as rescue medication, especially since their usefulness in 
decreasing symptoms have been demonstrated.
1
 In addition, the concomitant use of inhaled 
corticosteroids is usually allowed as well. A beneficial effect on (cardiovascular) mortality 
was suggested at first, but was challenged later on.
7,30,32,33
 Altogether, study results might be 
biased by the concomitant use of medication other than the study drug, and is usually not 
accounted for in analyses.
34
 In contrast to the recent large trials, our cohorts typically were 
without those limitations: during the Lung Health Study in the nineties, the benefit of 
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prescribing bronchodilation was not demonstrated yet, whereas our Dutch cohort was an 
observational study with no obligations on drug utilization. Furthermore, our trial on smoke 
retention included a wash-out period of individual bronchodilator treatments, and the cross-
over design accounted for alternative confounding by medication. 
 
Thirdly, discontinuation rates might cause bias as adherence is usually worse amongst the 
placebo group due to the fact that it does not improve disease symptoms. As a result, patients 
who continue to use placebo will generally be healthier than those patients who continue to 
use the trial treatment, which may negatively affect the treatment groups of randomized trials 
in particular.
13,35
 In contrast, adherence may also be protective due to better coping and 
lifestyle of the participant.
36
 Although our crossover trial would not have suffered from bias 
due to adherence, our cohort studies may have. It would mainly influence the effect of 
bronchodilation itself though. 
 
 
WHERE TO GO FROM HERE? 
 
There is a disparity between studies on safety profiles of different bronchodilators in COPD 
patients. Based on two large randomized controlled trials, prescription of long-acting beta-
agonists and long-acting muscarinic antagonists in COPD patients are currently supposed to 
be safe in the whole COPD population.
13,14
 In our studies, we explored the (cardiovascular) 
safety of bronchodilating agents in the subgroup of COPD patients who persist in their 
smoking habit. Our studies did not reveal a hazardous interaction between smoking and 
bronchodilation within the time-windows studied that would discourage the use of 
bronchodilators in these patients. However, it may still be possible that a beneficial effect of 
bronchodilators on disease risk is reduced by smoking. Furthermore, we did not study and 
therefore cannot exclude an interactive effect of smoking and bronchodilation on other 
smoking-related outcomes like COPD progression and/or lung cancer, nor did we study an 
effect on cardiovascular disease on the longer term. 
 
Another important note in the safe prescription of bronchodilators in COPD patients concerns 
the subgroup suffering from cardiovascular disease. Our cohort studies and most other studies 
on bronchodilator safety excluded a substantial part of COPD patients with cardiovascular 
disease at baseline. Hence, analyses that concern this subgroup of patients are lacking. 
Therefore, we recommend prescribing these bronchodilating agents with caution to those 
COPD patients with cardiovascular comorbidity. Similar caution might concern COPD 
patients with apparent asthmatic features as these patients are usually excluded from 
bronchodilator trials in patients with COPD. In addition, as we noticed the inability of several 
COPD patients to smoke cigarettes without sufficient bronchodilation, COPD patients with 
specific phenotypes may experience specific effects of bronchodilators on smoke-related 
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disease risk. This may warrant further investigations of a specific COPD phenotype once that 
phenotype appears typically prone for interaction between smoking and bronchodilators. 
 
In conclusion, as bronchodilators do not seem to worsen cardiovascular disease in COPD 
patients who continue smoking, these agents should always be considered in their treatment. 
However, as bronchodilating agents do not seem to significantly and/or relevantly improve 
prognosis, in smoking patients in particular, their prescription should be based mainly on the 
treatment of individual symptoms and the patient’s wellbeing. Furthermore, bronchodilators 
should still be prescribed with specific caution to those (smokers) with cardiovascular disease 
and/or asthma. 
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SUMMARY 
hronic Obstructive Pulmonary Disease (COPD) is a progressive chronic disease with 
a major impact on patients’ well-being, mortality, and health care costs. Although 
many studies determined the hazardous effect of smoking on both COPD and 
cardiovascular disease, the effects of bronchodilators have yet to be established. In order to 
clarify the reported discrepancies of different studies that concerned cardiovascular safety 
profiles of bronchodilators, we hypothesized an interaction between smoking and 
bronchodilators. In this thesis, we first explored the important characteristics of cigarette 
smoke in order to understand and discuss the measurements of smoke exposure. Next, we 
studied the interaction between smoking and bronchodilators by a variety of study methods 
that each explores a certain level in the cascade of interaction; starting with the fundamental 
mechanism of interaction on smoke retention, and followed by the ultimate effect on 
cardiovascular fatal and/or nonfatal events. 
 
In chapter 2.1, we demonstrated the existence of nanoparticles (diameter <100 nm) in fresh 
and undiluted cigarette smoke, with the smallest particles detected by our method measuring 6 
nm in diameter. The fraction of particles with a diameter of 6 to 100 nm would account for 
around five percent of the total number of particles. Hence, the weight contribution of light-
weighted nanoparticles would have a negligible effect on tar values expressed by mass units 
(weight). In addition, not all of these particles will be captured on the membrane filter that is 
normally used for the determination of tar mass. Vice versa, tar mass values poorly reflect 
nanoparticles as expressed by particle number. Although potentially toxic due to their small 
size, rapid ageing in high-concentrated cigarette smoke may cause most of these small 
particles to aggregate to larger particles within a timeframe of milliseconds. Moreover, a part 
of these larger particles may consequently be filtered out with tar mass measurements. 
Altogether, the attributive toxicity of nanoparticles in cigarette smoke appears small, although 
final assumptions on the extent of toxicity cannot be made based on our results. 
 
A more detailed description of the value of tar mass measurements to facilitate our trial on 
smoke retention is presented in chapter 2.2. It seems that tar mass yields from one cigarette, 
as declared on the label of cigarette boxes, poorly reflect the overall size-resolved distribution 
of particles, when measured by our method with optical spectrometry measuring particles 
with diameters of 250 nm and larger. In addition, smoking regimes have a major effect on tar 
yields, total particle numbers and size-resolved particle distributions, mainly by affecting the 
contribution of smaller particles. However, as smoking regimes mainly vary between 
individuals and less within individuals, reproducibility of size-resolved particle distributions 
and total particle numbers are acceptable with a coefficient of variance for our study cigarette 
of 22% within the same smoking regime. 
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Next, we presented our hypothesis of interaction in chapter 3.1, followed by a pilot study that 
explores to what extent this interaction affects the risk of cardiovascular events in chapter 3.2. 
This pilot study in COPD patients from primary care shows a protective effect of 
bronchodilation on cardiovascular ischemic events, as measured by the start of anti-platelet 
therapy and/or nitrates. An effect of interaction between bronchodilation and smoking was not 
confirmed, although the beneficial effect of bronchodilators appeared smaller in those COPD 
patients who smoked cigarettes compared to those who did not smoke cigarettes during the 
study period. 
 
In chapter 3.3 we described the development of our randomized crossover trial to study the 
effect of maximal bronchodilation on the pulmonary retention of cigarette smoke in COPD 
patients who smoke cigarettes. The final method included the measurement of smoke 
retention by tar and nicotine retention, and the minimization of variance by a crossover design 
and using one cigarette brand only. In chapter 3.4 we reported the results of this trial. In the 
primary analysis, a hazardous effect of bronchodilation on smoke retention was not 
confirmed. After excluding samples with a (presumably laboratory-based) contamination, a 
secondary analysis revealed a possible beneficial effect of bronchodilation on smoke 
retention, with a significant reduction of nicotine retention and a similar trend for tar. 
 
As cardiovascular toxicity due to cigarette smoking depends on many more smoking-related 
characteristics than pulmonary smoke retention alone, chapter 3.5 reports on the ultimate 
effect of interaction on cardiovascular disease. This chapter describes the results of a study on 
fatal and nonfatal cardiovascular events in a five year follow-up cohort of COPD patients who 
were all smokers at baseline. The patients included in our analyses had all been randomized 
into a treatment group of either bronchodilator or placebo prescriptions, and were all offered 
an intensive smoking cessation program. Although the cohort had a low incidence of 
cardiovascular events and it provided a relatively short period of smoking cessation which 
may have impaired the analyses, we did obtain a fair number of events. Altogether, we could 
not confirm any interaction between bronchodilation and smoking. 
 
In the discussion section in chapter 4, we claim that based on our study results, 
bronchodilation in COPD patients who persist in their smoking habit is safe. Although we 
studied a wide range of COPD patients with respect to age, sex, and severity and reversibility 
of airflow limitation, it is difficult to translate our results to other subpopulations, in particular 
to COPD patients with cardiovascular disease and those with asthmatic features. Some 
caution in prescribing bronchodilators in these specific subgroups remains recommendable. 
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Conclusion 
 
We conclude that bronchodilators do not seem to worsen (cardiovascular) outcome in COPD 
patients who continue smoking. Although these agents should always be considered in the 
treatment of COPD patients, the decision on their prescription should preferably be based on 
the effect of treatment on individual symptoms and the patient’s wellbeing. Caution might 
still be warranted in those (smokers) with cardiovascular disease and/or asthmatic features. 
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SAMENVATTING 
 
hronisch Obstructieve Longziekte (COPD) is een progressieve chronische ziekte van 
de luchtwegen, die het welzijn van patiënten beïnvloedt, alsmede hun 
overlevingskans en de kosten voor hun medische zorg. Roken wordt gezien als de 
belangrijkste oorzaak voor COPD, terwijl luchtwegverwijding de belangrijkste 
medicamenteuze behandeling is voor de klachten veroorzaakt door COPD. Alhoewel de 
negatieve effecten van roken op COPD en hart- en vaatziekten in vele studies zijn bewezen, is 
het lange termijn effect van luchtwegverwijders op deze ziekten nog omstreden. Wij 
veronderstelden een interactie tussen luchtwegverwijders en roken die de verschillende 
resultaten van onderzoeken over het lange termijn effect van luchtwegverwijders zouden 
kunnen verklaren. De veronderstelling is gebaseerd op een mogelijk ander inhaleer gedrag 
dan wel rookneerslag in de longen door luchtwegverwijding, waardoor de nadelige effecten 
van roken worden beïnvloed. In dit proefschrift worden eerst belangrijke eigenschappen van 
sigarettenrook onderzocht om daarmee beter de individuele blootstelling aan rook te begrijpen 
en te kunnen meten. Vervolgens bestuderen we het effect van de interactie tussen 
luchtwegverwijding en roken op individuele rookblootstelling en uiteindelijk het effect op 
cardiovasculaire ziekte. 
 
In hoofdstuk 2.1 bewijzen we allereerst het bestaan van nanodeeltjes (diameter <100 nm) in 
verse, onverdunde sigarettenrook. Het aandeel van door ons aangetroffen nanodeeltjes tussen 
de 6 en 100 nm zou echter maar zo’n 5 procent van het totaal aantal deeltjes zijn. Door hun 
kleine afmetingen zal hun aandeel in het sigaretten teer gehalte, gemeten in massa/gewicht, 
verwaarloosbaar klein zijn. Aan de andere kant bleek het teergewicht geen goede maat te zijn 
voor het aantal aanwezige nanodeeltjes. Alhoewel deze nanodeeltjes potentieel toxisch zijn 
door hun kleine afmetingen en zo potentieel makkelijk weefsel kunnen penetreren, hebben 
deze deeltjes de neiging om binnen milliseconden te aggregeren tot grotere deeltjes. Het 
uiteindelijke aandeel van deze nanodeeltjes op het toxische effect van sigarettenrook lijkt alles 
bij elkaar klein. 
 
De waarde van het protocollair meten van het teergewicht van sigarettenrook, middels binding 
aan specifieke Cambridge filters, om vervolgens te kunnen gebruiken in ons onderzoek over 
hoe luchtwegverwijders de neerslag van rook in de longen kunnen beïnvloeden, is beschreven 
in hoofdstuk 2.2. Hieruit blijkt dat het teergewicht van één sigaret, zoals op sigarettenpakjes 
staat vermeld, niet goed representatief is voor de op afmeting gebaseerde verdeling van 
rookdeeltjes. Daarbij bleek dat het aantal rookdeeltjes, hun afmeting en het totale teergewicht 
sterk beïnvloed worden door het rookregiem, welk vooral de vorming van kleine deeltjes 
beïnvloed. Echter, het rookregiem zal vooral verschillend zijn tussen personen, en niet zo zeer 
bij één persoon. Bij vergelijkingen binnen één persoon zal de meetmethode dus meer 
betrouwbaar en reproduceerbaar zijn. 
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In hoofdstuk 3.1 beschrijven we onze veronderstelling over mogelijke interactie tussen 
luchtwegverwijders en roken, gevolgd door hoofdstuk 3.2 waarin wordt verkend of deze 
interactie het risico op hart- en vaatziekte kan beïnvloeden. Deze verkennende studie laat zien 
dat luchtwegverwijding mogelijk beschermend kan zijn in patiënten met COPD van de 
huisartsen praktijk. Hoewel een interactie niet bevestigd werd, was het beschermende effect 
van luchtwegverwijding kleiner in de groep patiënten met COPD die sigaretten bleven roken, 
vergeleken met degenen die waren gestopt. 
 
In hoofdstuk 3.3 beschrijven we het ontwerp van onze gerandomiseerde crossover onderzoek, 
welke het effect van luchtwegverwijding op de neerslag van rook in de longen van COPD 
patiënten onderzoekt. De neerslag van rook word gemeten middels teer en nicotine neerslag 
als percentage van de ingeademde teer en nicotine. Het crossover model zorgt ervoor dat 
vergelijkingen tussen wel en geen luchtwegverwijding binnen één persoon worden gedaan. In 
hoofdstuk 3.4 worden de resultaten van dit onderzoek gepresenteerd. In de oorspronkelijke 
analyse konden we geen interactie bevestigen. Na exclusie van bevuilde monsters, liet een 
aanvullende analyse echter een mogelijk beschermend effect van de luchtwegverwijding op 
rookneerslag zien, met aanzienlijk minder nicotine en mogelijk ook minder teer neerslag.  
 
Het uiteindelijke effect van de interactie tussen luchtwegverwijders en roken op hart- en 
vaatziekte is beschreven in hoofdstuk 3.5. Hiervoor gebruikten we gegevens van rokers met 
COPD die vijf jaar gevolgd werden naar aanleiding van een gerandomiseerd aangeboden 
luchtwegverwijding en/of stoppen met roken programma. Voor alle deelnemers werden 
dodelijke en niet-dodelijke gebeurtenissen door hart- en vaatziekten geregistreerd. Met deze 
gegevens konden we geen interactie tussen luchtwegverwijders en roken bevestigen. Hoewel 
het aantal gebeurtenissen relatief laag was en de stoppen met roken periode relatief kort, 
beschikten we absoluut gezien over een aanzienlijk aantal gebeurtenissen. 
 
In hoofdstuk 4 bespreken we onze onderzoeksresultaten. Hierin bepleiten we dat bij patiënten 
met COPD die blijven roken gerust luchtwegverwijders kunnen gebruiken. Voor specifieke 
groepen zoals degenen met ook hart- en vaatziekte in de voorgeschiedenis of mensen met 
astma naast hun COPD zou een wat meer terughoudend beleid niet misstaan. 
 
 
Conclusie 
Wij concluderen dat luchtwegverwijders het risico op hart- en vaatziekten niet verhogen bij 
patiënten met COPD die blijven roken. Hoewel deze medicamenten altijd overwogen moeten 
worden in de behandeling van COPD, zal het uiteindelijke besluit ze te gebruiken vooral 
gebaseerd moeten worden op het effect van de behandeling op individuele klachten en op het 
welbevinden van de patiënt. Enige terughoudendheid door nog onvoldoende bewijs van 
veiligheid blijft aanbevolen bij de patiënten met COPD (die blijven roken) die ook een 
geschiedenis van hart- en vaatziekte en/of astma kenmerken hebben. 
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hospitalité nous avons eu a votre ville.  
Hennie Giesbers en collega’s van de technische dienst. Wat een heerlijkheid om samen het 
materieel van de experimenten uit te denken. Dank voor de productie van de vele onderdelen 
voor de opstellingen. Wat een feest was het ook om in de magazijnen door al het UMC afval 
te struinen en daar nog mooi materiaal vandaan weten te toveren. Wat je allemaal niet kan 
recyclen... 
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Rob Anzion. Wat fijn om altijd iemand in de buurt te hebben gehad die alles in goede banen 
kon leiden op het lab. Met veel dank heb ik van de faciliteiten gebruik gemaakt, en met veel 
plezier experimenten opgezet en uitgevoerd! Hopelijk rook de gang niet naar sigarettenrook 
na de proefjes en krijgt het materiaal in de diepste kelders van het UMC ooit nog een functie. 
Robbert, Joran, Simone, Monique, en Emmy. Met plezier heb ik samen met jullie aan alle 
onderzoeken gewerkt. Jullie gaven vaak een frisse kijk op het werk en zorgden voor 
inspiratie. Robbert, ik hoop dat je me de blauwe duimen kan vergeven.. 
Henk Luijsterburg. Bedankt voor je assistentie en support bij de ingewikkelde apparatuur voor 
spectometrie. Het duizelt me nog af en toe als ik de data zie. De haar in de spectrometer en de 
teeraanslag in de DMA waren momenten waar jij en Grimm ons goed in hebben geholpen. 
Glasblazers, bedankt voor het geduldig blazen van de glazen opvang bollen. Ik kijk er nog wel 
eens in, en zie in de spoortjes rook soms nog wat visioenen. Rookstoel, dank je wel voor de 
mooie zonsopgangen die ik met jou mocht genieten en de fijne artikelen die ik met de benen 
omhoog heb kunnen doorworstelen. Logopedist, bedankt dat je me ooit een beetje 
verstaanbaar hebt kunnen maken. Ik ben helaas een beetje laks geweest met het huiswerk. 
Guus en Renske, respectievelijk mijn 1
e
 en 3
e
 jaars opleiders. Naast het geduldige opleiden en 
ruimte voor mijn eigen ontwikkeling als HAIO, dank ook voor het vele begrip en flexibiliteit 
rondom het combineren van mijn opleiding met het onderzoek en mijn gezin. Ik heb bij jullie 
het vak en het plezier daarin mij voorspoedig eigen kunnen maken. 
Annelies, Twanny, Tilly en Caroline. Wat fijn was het om altijd op jullie te kunnen rekenen. 
Altijd hulpvaardig, meedenken en wegwijs maken in de organisatie en logistiek van het ELG. 
Lieve ganggenoten van de begane grond, dank voor de relaxte jaren. Het was altijd plezierig 
om naar ‘het werk’ te gaan. Een momentje sparren, koffie drinken of zonnen in het gras. 
Speciaal Joke bedankt voor de trouwe ondersteuning en fijne tijd als kamergenootjes! 
Reinier, bedankt voor alle statistiek adviezen. Het meeste kon vaak even tussendoor terwijl je 
andere dingen gaande had. Het gros is gelukkig bekleven, alhoewel een deel al weer in ‘rook’ 
is opgegaan. Succes met de voortzetting en afronding van jouw project! 
Aiotho’s en promovendi, oude garde en nieuwe garde, wat een heerlijk nest om mee samen te 
werken. Samen maken we het onderzoek tot een groot feest en houden we elkaar scherp. 
Dank voor de adviezen, sturing en lol! In het bijzonder Evelien, Erik en Hilde, mede-aiotho’s 
en kamergenootjes van het eerste en het laatste uur. Bedankt voor de gezelligheid, het sparren 
en de steun! Succes met jullie verdere carrières op huisartsen- en onderzoeksgebied. 
Roche & Corne, Cobus & Monica, Nel & ‘Hoffie’. Baie dankie vir die pragtige tyd en 
lewenslesse in Walvisbaai. Apart van die fees vier, het ek by julle (met terugwerkende krag) 
geleer wat beskeidenheid en waardering vir die bestaan en die werk hoort te wees. Ek wens 
julle baie voorspoed in dat wonderlike land. 
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Lieve tennismaatjes. Marije, Bibi, Wendy, Arjen, Kasper, Michiel, Renze, Thierry, Stephanie, 
Pauline, Mark en Karin. Wat een hele rij namen al weer voor NQ still loading (nu begrijp ik 
de naam eindelijk)! Bedankt voor alle avondjes en competities zorgeloos tennissen en 
nabieren. Hopelijk loaden we nog vrolijk een lange tijd door. 
Beste buren. Wat een luxe met jullie. Ons hebben en houden achterlatend met jullie naast ons 
geeft een hoop rust en vertrouwen. De jongens lopen graag bij jullie binnen, en dat zegt 
genoeg. Hopelijk volgen er nog veel zomerse pianoconcerten, koffies en wijntjes! 
Harm en Lieven. Mijn fiere paranimfen. Bedankt voor het mij bijstaan tijdens de verdediging. 
Ik hoop jullie ook zonder ape(n)pak nog lang aan mijn zijde te mogen hebben. 
Willem en Anne. Wij hopen ergens ook niet al te ver vandaan te zullen komen en nog vaak 
van elkaars gezelschap te kunnen genieten. Succes bij de dierentuin! Boris en Maaike, druk 
aan de andere kant van het land ben ik blij nog steeds af en toe van jullie kennis en 
gezelligheid te mogen genieten en de jongens lekker te kunnen laten stoeien. Jasper en Agnes, 
dank voor de humor en betrokkenheid. Veel plezier met jullie nieuwe aanwinst. Atsje en 
Andre. In Groningen elkaar misgelopen, bij de GGZ elkaar gevonden ;). Wat fijn om in jullie 
enthousiasme en vrolijkheid te kunnen delen. Veel geluk met de uitbreiding! Lieven en 
Charlotte, succes met al jullie projecten en veel geluk met jullie gezin ergens nabij België. 
Carolus, wat een beste tijd was dat in het bossche leven en wat heeft het veel bij elkaar 
gebracht… Wat leuk om te zien dat iedereen uiteindelijk toch dezelfde richting is ingedoken! 
Ik geniet nog veel van het samen komen en vind het heerlijk om lekker te kunnen ‘reflecteren’ 
(spuien?) over alle ervaringen. Succes in (het vinden van) de juiste praktijk! 
“Aussie Aussie Aussie, Oi Oi Oi“. How good it is to bring back memories and still once in a 
while dream away together to long gone paradises. I sure miss our ‘pleasurable pool parties’ 
but am happy to have traded those for the ‘chaotic kid’s gatherings’. 
AeMulatio. Acht mannen bij elkaar. Gaudeamus igitur, Juvenes dum sumus. Wat heeft de tijd 
gebracht en wat rest ons nog? Nog lang niet uitgepraat, uitgelachen en uitgezongen…. Wisten 
jullie overigens dat een goudvis een geheugen heeft van langer dan drie seconden? Dank voor 
de vriendschap. Ik wens jullie allen veel voorspoed, waar jullie ook moge verblijven. 
Gerrit & Angela. Met Sylvia heb ik 2 lieve en zorgzame schoonouders erbij gekregen. Geen 
afstand is jullie te ver om ons op te komen zoeken of om op de kinderen te passen (zelfs 
oppassen in Montreal). Heerlijk genieten van de momenten met een Chasse du Pape en een 
eind weg kletsen over van alles. De kinderen verheugen zich altijd op opa en oma bus (met en 
zonder treintjes!). Het chaletje wacht nog met veel geduld op jullie.. Margot & Pierre, Tanja 
& Gerjan. Wat een fijne schoonfamilie heb ik met jullie. Kerst met zijn allen op elkaar maken 
we altijd toch weer een feest van. Een rondje op de banken dansen is wel al weer een tijd 
geleden.. Met de jaren komen de gezonde gewoontes. Wie weet lopen we ooit nog de 7 
heuvels met zijn allen! Maar wie speelt er toch het liefst met treintjes? 
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Maarten en Steven. Als eeuwige kleine Dijkie met jullie als grote voorbeeld volgde ik jullie 
menigmaal in jullie kielzog. Een klein broertje in de nek hijgend is niet niks. Een balans 
tussen zelf laten ontdekken en bijsturen is lastig. Mijn prille rijbewijs in de broekzak het groot 
licht ontdekkend in de haarspeld bochten van de Alpen. Aan lukte wel, uit niet. Om de 
tegenligger maar niet te verblinden draaide ik het licht na verwoede pogingen in zijn geheel 
maar uit. Een op drift geslagen voertuig door het holst van de donkere nacht, zoevend langs 
de afgrond. Gegil vanaf de achterbank… Gevloek en getier. Klamme bleke gezichten keken 
me vervolgens aan toen ik in de herkansing ging. Die blikken heb ik de afgelopen tijd 
gelukkig niet meer zo vaak gezien. Ondanks dat ik toch wat minder kleine Dijkie ben 
geworden, is het nog steeds fijn twee grote broers te mogen hebben. Gerbrich en Brenda, 
alweer lange tijd bij de van Dijken. Samen 9 kleinkinderen alweer, chaos alom! 
Vrouwenpraat, theeleut en kinderverhalen. Ik doe er graag aan mee en verheug me op weer 
eens een rondje van Carcassonne & co.  
Lieve papa en mama. Wat een eindeloos, onbeperkt en onvoorwaardelijk geduld, vertrouwen 
en liefde hebben jullie voor jullie zoons, schoondochters en kleinkinderen. De touwtjes 
langzaam uit handen kunnen geven over de jaren en toch nog graag op de zijlijn kunnen staan. 
Een veilige haven in goede en slechte tijden. Met plezier kijk ik terug op al jullie bezoekjes in 
verre oorden! Inmiddels hebben jullie een uitgebreide schare onder jullie ‘hoede’, en zijn 
jullie altijd bereid om bij te springen. Fijn dat jullie daar ook heerlijk van kunnen genieten en 
dat deze nieuwe fase in jullie leven jullie goed lijkt te vallen. 
Lieve Sylvia. Wat hebben wij samen al veel meegemaakt, gelukkig vooral een heleboel 
heerlijkheden en mooie herinneringen. Onze danspasjes oefenen in Perth, Walvissen spotten 
in Charlevoix, en duinen beklimmen in Sossusvlei. Met z’n tweeën en later met z’n vijven de 
wereld over, wie weet wat en waar de toekomst ons brengen zal? Een promotietraject in 
woelige tijden, wat zou dat voor goeds en kwaads brengen? Als steunpilaar langs de zijlijn 
mijn stress aanhorend leer jij mij juiste keuzes maken. In de tussentijd ben je mij ook nog 
komen vergezellen bij de huisartsen opleiding. Treffen wij elkaar ooit onder nóg een dak? 
(retorische vraag?) Samen de ballen proberen hoog te houden en de dagelijkse planning met 
elkaar proberen rond te krijgen heeft nog steeds nogal wat voeten in aarde. Ik ben blij dat ik 
dat met jou mag doen. Met Simon, Morris en Hugo hadden we niet mooier kunnen wensen. 
Jongens, jullie zijn papa’s grote trots. Met jullie schaterlach en twinkelende boevenoogjes zijn 
jullie een heerlijke bron van genot en energie. Stuiter er maar lekker op los. Ik geniet van 
jullie enthousiasme over kleine dingetjes en van jullie nieuwsgierigheid voor het leven (sorry 
Simon, Nederland is niet plat doordat Rollie er overheen heeft gereden..). Met kleine stapjes 
de wereld ontdekken (met zaklamp op zoek naar kabouters, skiën tussen de benen van papa, 
met letters woorden kunnen maken). Wat is het heerlijk om ons samen te verwonderen over 
de mooie dingen in het leven. 
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